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Abstract
The advancements in high-throughput technologies have made it possible to generate a huge number of “omics” data, including genomics, proteomics, transcriptomics,
epigenomics, metabolomics, and microbiomics. Combining multiple data sources and
performing joint analyses with all available information and the phenotypic outcome
can reflect various aspects in complex biological systems, such as revealing regulation
processes, discovering novel associations between biological entities, and identifying
relevant biomarkers for certain diseases or phenotypic outcomes. This dissertation focuses on developing statistical models for analyzing multi-omics data. It is comprised
of three topics: (1) integrative analysis for multi-omics data with missing observations in intermediate variables; (2) modeling the dynamic gene co-expression (DC) in
a genome-wide search space with the implementation of variable selection techniques
in a Bayesian framework; and (3) mixed-effect variable selection model for identifying DC using scRNA-seq count data and DC-based strategy in subject subgroup
classification.
In Chapter 2, we propose a novel integrative multi-omics analytical framework
based on p-value weight adjustment in order to incorporate observations with a large
proportion of missing values in the analysis. The occurrence of missing values is an
inevitable issue in multi-omics data because some measurements, such as mRNA gene
expression levels, often require invasive tissue sampling from patients. To incorporate the incomplete information from measurements with missing records, we split
the data into a complete set with full information and an incomplete set with missing measurements, and introduce mechanisms to derive weights and weight-adjusted
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p-values from the two sets. Through simulation analyses, we demonstrate that the
proposed framework achieves considerable statistical power gains compared to a complete case analysis or multiple imputation approaches. In experimental data analysis,
the implementation of our proposed framework is illustrated by a joint analysis of
DNA methylation, mRNA, and the phenotypic outcome in a study of preterm infant
birth weight.
Chapter 3 proposes two models to apply the genome-wide search for identifying
dynamic gene co-expression from genomic datasets. In a biological system, genetic
interactions are tightly regulated and are often highly dynamic. The interactions
can change flexibly under various internal cellular signals or external stimuli. Previous studies have developed statistical methods to examine these dynamic changes
in genetic interactions. However, a common challenge encountered in the existing
approaches is the computational intensiveness due to the massive number of gene
combinations needed to be considered in a typical genomic dataset, yet often a much
smaller proportion of gene interactions exhibit dynamic co-expression changes.
To solve this problem, we propose variable selection methods in Bayesian frameworks with spike-and-slab priors. The proposed algorithms focus on subsets of promising gene combinations in the search space. We also adopt a Bayesian false discovery
control procedure for testing the significance of dynamic gene co-expression changes.
A series of simulation studies are then conducted to present a comparison between
our proposed approaches to the existing exhaustive search heuristics. We also demonstrate the implementation of our proposed approaches in experimental data analysis
to study gene co-expression changes associated with colorectal cancer recurrence-free
survival.
In Chapter 4, we develop subject-specific methods which combines mixed-effect
model and spike-and-slab variable selection method in identifying DC for scRNA-seq
read count data. In a typical scRNA-seq dataset, gene expression profiles are usually
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collected from multiple subjects such as different patients or tissues. Considering
subject-specific characterization can increase the accuracy of identifying DC and the
sparsity of DC signals in scRNA-seq datasets, we propose a mixed-effect variable
selection model for identifying subject-specific DC gene pairs while incorporating both
subject-specific random effects, across-specific fixed effects, zero-inflation and overdispersion in scRNA-seq datasets. We also propose a DC-based strategy to classify
subjects into subgroups by using subject-specific DC as inputs. Through simulation
study, we show that our proposed ME-SPSL model outperforms the mixed-effect
model without using variable selection technique and the existing method without
considering subject-specific random effects. We also demonstrate the implementation
of our proposed method in a melanoma scRNA-seq dataset to estimate subject-specific
DC and use the DC gene pairs as the biomarkers to classify the melanoma samples
into immunotheropy-resistant and non-resistant groups.
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Chapter 1
Introduction
1.1

Multi-omics Integrative Analysis

Advancements in high-throughput technologies have enabled the generation of largescale multi-omics data from multiple sources. Increasingly, multi-omics data such as
DNA sequences, copy number variations, methylation, miRNA, and gene expression
are collected from the same individuals in biomedical studies. The benefits of combining multiple data sources and performing joint analyses with all available genomic
information and the phenotypic outcome are multifold. First, different data types
could reflect various aspects of the underlying biological system (Song et al., 2020;
Kristensen et al., 2014). Second, if multiple data sources all pinpoint the same gene
or pathway, then it is less likely to be a false positive. Third, combining data from
various sources can lead to a better statistical performance in detecting signals among
the noise.

1.2

Missing Values and Data Imputation Algorithms

In integrative multi-omics data analysis, mRNA gene expression often serves as the
intermediate variable in many underlying etiological mechanisms. Due to the fact
that mRNA measurements often require invasive tissue sampling from participants,
it is common to obtain a large portion of the data with missing values in mRNA
gene expression measurements as shown in Figure 2.1. A straightforward approach
for handling missing values is to implement a complete case analysis by removing
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observations with incomplete information (Guillermo et al., 2021; Ramaswami et al.,
2020; de Silva and Perera, 2017). Another solution could be to apply imputation
methods (Lin et al., 2016; Rubin, 2004; Van Buuren and Groothuis-Oudshoorn, 2011;
Troyanskaya et al., 2001; Shah et al., 2014). Multiple imputation (Rubin, 2004) is
a widely used solution to the missing value problem. Van Buuren and GroothuisOudshoorn (2011) developed a useful tool, multivariate imputation by chained equations (MICE), for implementing multiple imputation to iteratively generate missing
values from conditional distributions on the basis of the observed data while considering the relationships between variables.
Although imputation methods offer practical alternatives for handling missing
values, in the situation where there is a high rate of missing values, imputation
approaches might not perform well (Yang et al., 2014; Yu et al., 2020). Multiple
imputation algorithms such as MICE can quickly become computationally intensive
as the number of variables with missing values increases (Ratolojanahary et al., 2019).
Furthermore, imputation methods mainly use information from single omics data
rather than considering the connections among multi-omics data, which can lead to
biases in the final imputation (Lin et al., 2016).

1.3

Dynamic Gene Co-expression

High-throughput technologies have generated a wealth of gene expression data and
provided exciting opportunities to study genetic regulations and interactions in biological systems. Genetic interactions, often tightly regulated and highly dynamic
in a complex regulatory network (Green et al., 2009; Sambandan et al., 2006; Qiu
et al., 2011; Yu, 2018), can be activated or switched off in response to changes in
cellular signals or environmental conditions. Changes in cellular states and modulatory patterns can result in changes in correlations between genes (Li, 2002; Lai et al.,
2004).
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In the literature (Li, 2002; Gunderson and Ho, 2014; Kinzy et al., 2019; Yang
and Ho, 2021), the dynamic change in gene correlation was referred to as dynamic
gene co-expression (DC). It was defined as the conditional correlation between the
expression levels of two genes X1 and X2 given a modulating factor Z, ρ(X1 , X2 |
Z = z) = E(X1 X2 | Z = z), when X1 and X2 have zero means and unit standard
deviations.
Previous studies have established several statistical methods for quantifying DC
(Li, 2002; Lai et al., 2004; Ho et al., 2011; Kinzy et al., 2019). Li (2002) proposed
a direct approach named liquid association (LA) to measure the dynamic pattern
of co-expression between two genes modulated by the expression level of a third
gene. He defined a LA score to describe the expected changing rate of co-expression
′

towards the modulatory variable Z as follows, LA(X1 , X2 | Z) = E(g (Z)), where
g(Z) = ρ(X1 , X2 | Z). By assuming the gene expression levels to be standard normal,
the conditional correlation can be written as the expected value of the product of gene
expression levels, ρ(X1 , X2 | Z) = E(X1 X2 | Z). According to the Stein’s lemma, if
Z follows the standard normal distribution, the magnitude of DC can be quantified
based on the three-product moment estimator:

1
n

Pn

i=1

xi1 xi2 zi (n is sample size).

However, the assumption that the modulating factor (Z) follows a standard normal distribution might be violated when considering to other types of modulators,
such as patients survival time or cancer metastatic potency. To relax the normality
assumption, Ho et al. (2011) extended Li’s work and proposed a conditional normal
model (CNM) to quantify DC. In relevant pathways or whole-genome datasets, this
approach can be implemented by searching through all possible gene pair combinations (Gunderson and Ho, 2014; Kinzy et al., 2019). However, when the number
of genes under consideration increases, this exhaustive search (ES) strategy quickly
become computationally intractable. In a typical genomic dataset, often a much
smaller proportion of gene interactions exhibit dynamic co-expression changes. This
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issue motivated us to focus on the promising gene set combinations during the search
process.

1.4

Bayesian variable selection: Spike-and-slab priors

Li’s work (Li, 2002) established a concise method for quantifying DC using gene expression modulators. However, the normality assumption cannot be fulfilled when
it comes to other types of modulating factors, such as RNA-seq data or cancer
metastatic potency. Thus developing methods with more flexibility on the distribution of modulating factors can be beneficial in the discovery of underlying regulatory
mechanisms.
On the other hand, DC signals between gene pairs with respect to a modulating
factor in a genomic dataset can be highly sparse. A large proportion of gene-pair
combinations only exhibit weak DC signals. The original LA and similar approaches
generally implement a genome-scale scan over all possible gene-pair combinations (Li,
2002; Li et al., 2004; Lai et al., 2004; Ho et al., 2011; Kinzy et al., 2019; Yang and
Ho, 2021). As the dimensionality of genome-wide gene-pair combinations approaches
billions (108 ∼ 1010 ), this scanning strategy quickly becomes computationally intractable. Applying screening measures (Gunderson and Ho, 2014; Yu, 2018) was a
frequently used remedy for the issue of dimensionality. However, even the screening
techniques can effectively reduce the search space to a smaller subset containing a
larger proportion of gene pairs with significant DC signals, sparsity remains an issue
in the subset for DC estimation.
Motivated by these two issues, we proposed a novel DC model with the implementation of the variable selection technique in a Bayesian framework. First, we assumed
a linear relationship between ρ(X1 , X2 |Z) and Z with a link function of Fisher’s Ztransformation as suggested by Ho et al., (2011), Kinzy et al., (2019) and Yang et
al., (2021) (Ho et al., 2011; Kinzy et al., 2019; Yang and Ho, 2021). The modulating
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factor Z is the predictor without the normality assumption so that a broader range
of factors can be considered in the proposed model. Second, the variable selection
technique was used for systematically studying associations within a sparse matrix
by shrinking insignificant signals towards zero and yielding a parsimonious model.
Third, by constructing a multivariate variable selection model, we could consider the
dependencies among the gene-pair combinations and improve the effectiveness of DC
estimation.
It is noted that solutions for variable selection are available in both frequentist and
Bayesian frameworks. Adopting a variable selection method in a Bayesian perspective
offers several advantages (Van Erp et al., 2019). First, it is available to incorporate the
prior knowledge in the estimation process and derive the posterior distribution of the
parameters of interest. Second, Bayesian approaches estimate the shrinking parameter that controls the shrinkage effect using a prior mechanism. The Markov Chain
Monte Carlo (MCMC) sampling technique provides greater computational flexibility
for parameter estimation. Third, the Bayesian framework facilitates a more natural
and intuitive interpretation of parameters. For instance, a shrinkage parameter that
is tightly concentrated at 0 can be interpreted as that the corresponding coefficient
is dropped out.
We incorporate the spike-and-slab priors in the Bayesian variable selection framework to identify sparse signals among a large set of possible gene combinations. Compared to ES, the searching process can be drastically improved by identifying smaller
subsets of promising gene combinations with significant nonzero effects while shrinking other small coefficients to zero (George and McCulloch, 1993).
The spike-and-slab prior, first proposed by Mitchell and Beauchamp (1988), is a
scaling mixture of two distributions, one of which concentrates at 0 and the other of
which disperses. George and McCulloch (1993) defined the discrete spike-and-slab
prior, which is a frequently used prior in the Bayesian variable selection framework.

5

Let β = {βj : j = 1, ..., q} be a vector of parameters of interest in a Bayesian model.
The general form of the discrete spike-and-slab priors is represented by a normal
mixture,
ind

βj | sj ∼ sj N (0, v 2 ) + (1 − sj )N (0, cv 2 ),
ind

sj ∼ Bernoulli(pj ),
where v 2 is a small value and c is a large value to generate a large variance (e.g. v 2 =
0.01 and c=10,000 so that cv 2 = 100). The variable sj determines whether the “spike”
part with a smaller variance or the “slab” part with a larger variance is activated.
The probability of the selection is given by P (sj = 1) = 1 − P (sj = 0) = pj . When
pj is close to 0, the parameter βj will shrink to 0 with high probability.
The point mass measure at zero was widely used on the “spike” part of the discrete
spike-and-slab priors (Lee et al., 2017); however, the computation was challenging due
to the discrete probability measures (Shin and Liu, 2021). To address this problem,
Ishwaran et al. (2005) developed continuous spike-and-slab priors by introducing continuous bimodal priors with the following hierarchical structure:
ind

βj | γj , vj2 ∼ N (0, γj vj2 ),
i.i.d.

vj2 | α1 , α2 ∼ IG(α1 , α2 ),
ind

γj ∼ wj I1 + (1 − wj )Iv0 ,
i.i.d.

wj ∼ U (0, 1),
where α1 and α2 are the shape and scale parameters of the inverse gamma distribution,
and Iv0 refers to the point mass measure concentrating at a small value v0 (e.g. 0.005).
The hypervariance of the normal prior is the product of two parameters, γj and
vj2 . The scaling parameter γj controls the shrinkage effect while vj2 describes the
variance (Polson and Scott, 2010). With different γj and vj2 values, various bimodal
inverse gamma distributions can be constructed, which is either centered near 0 or
spreading out. On the basis of the continuous spike-and-slab prior (Ishwaran et al.,
6

2005), we developed our variable selection method to systematically study DC with
sparse signals.

1.5

Structure of the dissertation

The rest of the dissertation is organized as follows. In Chapter 2, integrative multiomics analysis models are proposed for incorporating incomplete information in intermediate variables using weighted p-value adjustment approaches. We describe the
proposed weighted p-value mechanisms in Section 2.3. In Section 2.4, a series of
simulation studies are presented in both low-dimensional cases and high-dimensional
cases to demonstrate the advantages of our proposed approach compared to imputation algorithms in various aspects. To illustrate the implementation of the proposed
approaches in real cases, we apply them to jointly analyze DNA methylation, gene
expression, and phenotypic outcome in a preterm infant birth weights study in Section 2.5. Finally, the conclusion and future studies are discussed in Section 2.6.
In Chapter 3, we propose two models to systematically identify dynamic genecoexpression in whole-genome datasets using Bayeisan variable selection techniques
with spike-and-slab priors. Section 3.1 reviews the main issues and the related literature. Section 3.2 provides an overview of the dataset. Section 3.3 introduces the
proposed approaches and describes the estimation processes. Section 3.4 presents
two simulation studies in both low- and high-dimesional search spaces with different
degrees of sparsity, which illustrates the advantages of implementing the proposed
models compared to the existing exhaustive search strategy. Section 3.5 demonstrates
the implementation of our proposed approaches with the experimental data analysis
on a colorectal cancer (CRC) dataset. In Section 3.6, we provide some discussions
and suggestions for future research on the related topics.
In Chapter 4, we proposed a mixed-effect variable selection model to study the
subject-specific DCs for zero-inflated and over-dispersed scRNA-seq count data to
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account for both the random effect of each subject and the fixed effect across all
subjects on DC. A DC-based classification strategy is proposed to implement subgroup classification using identified subject-specific DC gene pairs as the biomarkers.
Section 4.1 provides an overview of the background and the idea of our proposed
method. Section 4.2 elaborates the proposed methods and introduced the melanoma
dataset used in this chapter. Section 4.3 presents three simulation studies to illustrate
the performance of the proposed methods in subject-specific DC identification and
subgroup classification. In Section 4.4, we illustrate the implementation of our proposed methods through an experimental data analysis using the melanoma dataset to
estimate the subject-specific DC and implement the immunotheropy-resistant sample
classification. At the end, Section 4.5 provides discussion for the proposed methods
and the future work in the related area.
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Chapter 2
Multi-omics integrative analysis for incomplete
data
2.1

Introduction

The advancements in high-throughput technologies provide exciting opportunities to
obtain multi-omics data from the same individual in a biomedical study. Joint analyses of data from multiple sources offers many benefits. However, the occurrence of
missing values is an inevitable issue in multi-omics data because some measurements,
such as mRNA gene expression levels often require invasive tissue sampling from patients. Common approaches for addressing missing measurements include analyses
based on observations with complete data or multiple imputation methods.
To solve this issue, we propose a novel integrative analytical framework using
weighted p-value adjustment approaches to incorporate both the complete and incomplete (with missing mRNA gene expression measurements) observations in multiomics analyses. The weighted p-value adjustment approaches were proposed in the
context of multiple hypothesis testing to incorporate external information or prior
knowledge while maintaining the type I error rate (Roeder and Wasserman, 2009).
Several weighting procedures have been proposed in the literature, such as weighted
Bonferroni method for family-wise error rate (FWER) control (Roeder and Wasserman, 2009; Li et al., 2013), weighted Benjamini-Hochberg (BH) method (Genovese
et al., 2006; Habiger, 2017) and q-value method (Storey and Tibshirani, 2003; Storey
et al., 2004) for false discovery rate (FDR) control, and grouped FDR methods (Igna-
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tiadis and Huber, 2021; Roquain and Van De Wiel, 2009). To ensure the independence
between p-values and the derived weights (Roeder and Wasserman, 2009), the sample
splitting strategy (Rubin et al., 2006; Roeder et al., 2007) provides a useful tool that
uses a subset of the data to generate weights and the remaining data to compute
p-values.
In our proposed approaches, we split the samples into a complete set with full
information and an incomplete set with missing mRNA gene expression measurements. Two weighted p-value mechanisms (general and reverse weighting schemes)
are proposed. Compared to integrative procedures that utilize Markov chain Monte
Carlo such as iBAG (Wang et al., 2013), Bayesian integrative model (Fridley et al.,
2012), multi-dataset integration (Kirk et al., 2012), and Bayesian consensus clustering (Lock and Dunson, 2013), our proposed approach is fast and computationally
simple for a whole-genome study. Computational efficiency is particularly critical for
integrating multi-omics data since the interactions between multiple data types grow
exponentially with the number of variables considered in the study.
This chapter is structured as follows. The experiemental datasets used in this
chapter is described in Section 2.2. Next, the details of proposed weighted p-value
mechanisms are presented in Section 2.3. In Section 2.4, we implement three simulation studies in both low- and high-dimensional cases to demonstrate the advantages of
our proposed approach compared to the existing imputation algorithms and completecase studies. To illustrate the use of our proposed approaches, we apply the proposed
models to jointly analyze DNA methylation, gene expression, and phenotypic outcome in a preterm infant birth weights study in Section 2.5. Finally, we conclude this
chapter and discuss the future areas of research in Section 2.6.
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2.2

Datasets and Databases

The dataset utilized in this chapter is from a genetic association study for preterm
infants by Kashima et al. (2021) and can be accessed at Gene Expression Omnibus
(GEO) with accession number GSE110828. This study contains 157 observations
with DNA methylation and phenotypic outcome information. However, mRNA gene
expression measurements were collected for only 55 observations (65% missing). DNA
methylation levels were measured using the Ilumina HumanMethylation450 BeadChip
for 410,735 cytosine-phosphate-guanine (CpG) sites and reported after quantile normalization and background correction. The mRNA gene expression levels of 46,789
transcripts were profiled using the SurePrint G3 Human GE microarray 8×60K version 3.0 (Agilent Technologies). Transcriptional activities were analyzed using GeneSpring14.5 to perform probe-filtering and quantile-normalization to report the gene
expression signal levels.

2.3

Models

Let Y = (Y1 , ..., Yn )T be the vector of phenotypic outcome with n representing the total number of subjects, X be the matrix of clinical covariates, and M = (M1 , ..., Mq )
be the matrix of DNA methylation levels of q CpG sites, where Mj = (M1j , ..., Mnj )T ,
j = 1, ..., q, is the vector of methylation levels for the j-th CpG site. Let G =
(G1 , ..., Gd ) be the matrix of standardized mRNA gene expression data (mean = 0
and standard deviation = 1) of d genes and Gl = (G1l , ..., Gn1 l )T be the vector of
expression levels for the l-th gene (l = 1, ..., d) with n1 representing the number of
subjects of gene expression data (n1 ≤ n). All subjects can be split into two subsets:
a complete set (Z (1) = (M (1) , Y (1) , X (1) , G)) with n1 subjects where mRNA expression data can be observed and an incomplete set (Z (2) = (M (2) , Y (2) , X (2) )) with n2
subjects where the mRNA gene expression data are completely missing. The total
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number of subjects is n = n1 + n2 . Figure 2.1 provides a schematic diagram for this
data structure.
# of CpG sites: q

# of genes: d

# of outcome: 1

DNA
Methylation
Data

Gene
Expression
Data

Phenotypic
Outcome

M(1)

G

Y(1)

Complete set: Z(1)
# of subjects : n1

# of all subjects:
n = n1 + n2

M(2)

Y(2)

Incomplete set: Z(2)
# of subjects : n2

Figure 2.1. The schematic diagram for partitions of the complete set and incomplete
set in datasets with missing intermediate mRNA measurements. Dimensions, sample
sizes, the complete set, and the incomplete set are shown in the plot.

2.3.1

General weight

In the complete set, Z (1) , we implement the integrative analytical framework (IG)
suggested by Zhao et al. (2014) to integrate the DNA methylation, mRNA gene
expression data, and the phenotypic outcome to derive the p-value (pIG
j ) for testing
the association between the j-th DNA methylation measurement (j = 1, ..., q) and
the phenotypic outcome. Briefly, pIG
is calculated via two linear models formulated
j
as follows:
(1)

(1)

E(Yi |Gi , Xi ) =

(1)

α0 + GTi αG + (Xi )T αX
(1)

(1)

GTi αG = β0j + βMj Mij + (Xi )T βX + uij ,
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(2.1)
(2.2)

where α0 and β0j are intercepts; αG and αX are coefficients describing the associations between mRNA gene expression, clinical covariates, and the outcome. The parameter of interest, βMj , measures the association between the j-th DNA methylation
level and the phenotypic outcome via the regulation of mRNAs; and uij ∼ N (0, σu2 )
d
d
is the error term (i = 1, ..., n1 ) with variance σu2 . Let α
G and βMj be the estimates
d
of αG and βMj = 0. In practice, βd
Mj can be estimated via Equation (2) using α
G

derived from Equation (1). Under the null hypothesis of no association between Mj
d
d
and Y (βMj = 0), the p-value (pIG
j ) can be calculated based on βMj and var(βMj ).

In the incomplete set, Z (2) , we implement the linear model as follows:
(2)

Yi

(2)

(2)

= γ0j + γMj Mij + (Xi )T γX + ϵij ,

(2.3)

iid

where ϵij ∼ N (0, σϵ2 ), i = 1, ..., n2 and j = 1, ..., q, is the error term with variance
σϵ2 ; γ0j is the intercept and γMj represents the association between j-th methylation
data measurement and the phenotypic outcome; and γX is the vector of coefficients
LM
for the covariates. Let γd
Mj be the estimate of γMj . The p-value (pj ) can be derived

based on γd
Mj and var(γd
Mj ) under the null hypothesis γMj = 0.
In the general weighting scheme, the p-value derived from the incomplete set
(pLM
j ) is used to generate the weight. According to Li et al. (2013), we choose
wGj =

q

LM
−log10 (pLM
< 0.05, and set wGj = 1 otherwise, as the functional
j ) when pj

form to incorporate the information of the association between Mj and Y into the
weights. Since smaller p-values are associated with null hypotheses that are more
likely false, the proposed weights are anticipated to be positively correlated with
optimal weights and perform well (Habiger, 2017). To control the type I error, the
∗
general weights are then divided by the average weight wG
=
j

wGj
wG

(wG =

1
q

Pq

j=1

wGj )

∗
to ensure wG
= 1 (Genovese et al., 2006; Wasserman and Roeder, 2006). Finally, the

adjusted p-values for general weighting scheme can be calculated as p1j =

pIG
j
∗
wG

j
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.

2.3.2

Reverse weight

The general weighting scheme is more effective when the missing rate of gene expression data is low. When the missing rate is high (i.e. > 50%), we propose a reverse
weighting scheme to increase the power of identifying significant CpG sites. This
approach to deriving weights by a reverse weighting scheme is similar to the general
weighting scheme but uses a complete set (Z (1) ) to obtain weights while deriving
p-values using the incomplete set (Z (2) ).
In the incomplete set, Z (2) , the p-value (pLM
Mj and var(γd
Mj )
j ) is derived based on γd
from the linear model as described in Equation (2.3). Then, the weights are calculated
(1)
in terms of pIG
) by implementing the IG model.
j obtained from the complete set (Z

The reverse weight is set to be wRj =

q

IG
< 0.05 and wRj = 1
−log10 (pIG
j ) when pj

∗
=
otherwise. Then the weights are adjusted by the average value as follows, wR
j

(wR =

1 Pq

j=1

q

wRj
wR

∗
wRj ) to ensure wR
= 1 (Genovese et al., 2006; Wasserman and Roeder,

2006). Finally, we derive the p-value adjusted by the corresponding reverse weight,
p2j =

pLM
j
∗ .
wR
j

LM
The null hypotheses are βMj = 0 and γMj = 0 corresponding to pIG
j and pj , re-

spectively, in the general and reverse weighting scheme. According to Zhao et al.
(2014) when Equation (2.1) and (2) hold, we can plug Equation (2) into Equation (2.1), hence the null hypothesis βMj = 0 is equivalent to γMj = 0. Next, we
present an omnibus approach to combine the weight adjusted p-values (p1j , p2j ) from
the two weighting schemes.

2.3.3

Omnibus Method

For this study, we also consider an omnibus approach, the Aggregated Cauchy Association Test (ACAT) (Liu et al., 2019; Liu and Xie, 2020), to combine the adjusted
p-values from the general weighting scheme and the reverse weighting scheme. The
ACAT calculates the test statistic via a weighted sum of Cauchy transformations of
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the component p-values and assumes the test statistic to follow a Cauchy distribution
under the null hypothesis. The test statistic for the j-th CpG site (j = 1, ..., q) is
given by,
TjACAT = (1 − λ) × tan{(0.5 − p1j )π} + λ × tan{(0.5 − p2j )π},

(2.4)

where two component models (p1j for general weighting scheme and p2j for the reverse
weighting scheme) are combined in the ACAT and λ is determined by the missing
rate. The general scheme is more powerful in a low missing rate dataset, while the
reverse scheme becomes more effective when the missing rate is greater than 50%.
To maintain a desirable performance under various missing rates, we chose the λ
in terms of the missing rates of gene expression data (0 ≤ λ ≤ 1). Thus, we could
emphasize the general weighting scheme in studies with low missing rate and prioritize
the reverse weighting scheme in high-missing-rate studies.

2.4

Simulation

We conducted simulation studies to compare the performance of the proposed weighting approaches to the IG method (Zhao et al., 2014), the popular MICE imputation
(Van Buuren and Groothuis-Oudshoorn, 2011) and the K-nearest neighbor (KNN)
imputation method (Batista et al., 2002) under three scenarios. In this section, we
use the notation γM G to describe the DNA-gene association between DNA methylation (M ) and gene expression (G), and γGY to denote the gene-phenotype association
between gene expression (G) and the phenotypic outcome (Y ). Since there were 157
observed subjects in the experimental data set, we generated n = 150 samples in all
scenarios and studied the power of models averaged over 1,000 simulations.
The following steps describe the data generation procedures for Scenarios I and II
with low-dimensional gene expression data. For the i-th subject, we first generated
data for q = 5 DNA methylation loci (Mi ) and r = 2 clinical covariates (Xi ) indepen-
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dently from standard normal distributions. A single CpG site (Mi1 ) was selected to
be the true underlying methylated CpG site associated with the phenotypic outcome
through the regulation of the mRNA gene expression of three modulating genes.
In the second step, we considered d = 8 genes with expression levels (Gi ), of
which three genes were simulated based on the underlying CpG site (Mi1 ) via the
linear model,
Gi = γ0G + Mi1 γM G + XiT γXG + ϵi1 ,

(2.5)

where γM G is the vector of DNA-gene association; and ϵi1 ∼ N (0, I) and I is an
identity matrix. The values of the intercept (γ0G ) were determined based on the
mean expression levels of randomly selected genes from the experimental dataset. The
values of the elements in the coefficient vectors (γXG ) were all set equal to 0.5. The five
other independent genes served as unrelated signals and were generated independently
from the normal distribution, N (µ0G , 1), where µ0G was also determined by the mean
expression level of a randomly picked gene from the experimental dataset.
In the third step, we simulated the phenotypic outcome (Yi ) based on the mRNA
expression levels of the three modulating genes, according to the second linear model,
Yi = γ0Y + GTi γGY + XiT γXY + ϵi2 ,

(2.6)

where ϵi2 ∼ N (0, 1) is the error term with the variance of the phenotypic outcome
being set equal to 1. Here the intercept (γ0Y ) was set equal to the mean birth
weight score of the preterm infants in the experimental dataset, and the associations
between the clinical covariates and the phenotypic outcome (γXY ) were all set equal
to 0.5. For simplicity, we also assumed the same values for all the elements in the
vector γGY . After generating n = 150 subjects, which is close to the sample size
of the experimental dataset, multiple records of gene expression levels were removed
completely at random.
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2.4.1

Scenario I

After obtaining the weight-adjusted p-values via the proposed weighting schemes, we
considered two multiple testing adjustment procedures, one is the weighted Bonferroni method (Bland and Altman, 1995) for maintaining FWER and the other is the
weighted BH method (Benjamini and Hochberg, 1995) for FDR control. We set both
γM G and γGY equal to 0 and reported the results for both the FWER and the FDR at
the nominal level of 0.05 (Table 2.1). The FWER was calculated as the proportion of
times that at least one significant CpG site was observed among all CpG sites. The
FDR was calculated as the ratio of falsely detected CpG sites after the BH procedure.

2.4.2

Scenario II

In this scenario, we set the missing rate of gene expression data to 20% (low), 50%
(medium), and 70% (high) to assess the power of the proposed methods for identifying
the underlying CpG site (M1 ) with different amounts of missing gene expression
data. To comprehensively present the performance of the methods under various
combinations of DNA-gene and gene-phenotype associations, γM G was set equal to 0,
0.1, 0.2, and 0.5, and γGY was set equal to 0.1, 0.2, and 0.5. The empirical power of
detecting M1 over 1,000 simulations was reported.

2.4.3

Scenario III

In this scenario, we considered 1000 mRNA expression measurements and assumed
that the underlying DNA methylation (Mi1 ) was associated with the phenotypic
outcome for the i-th subject (Yi ) through the regulation of k = 5 genetic pathways
(fi ). The associations between gene expression levels (Gi ) and the pathway activities
(fi ) could be estimated using a factor model,
Gi = Bfi + Ui ,
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(2.7)

where fi ∈ Rk (k < p) is the vector of latent factors with cov(fi ) = Ik , Ui ∈ Rp
is the error term, and B ∈ Rp×k is the loading matrix describing the gene-factor
associations.
Data simulation was performed in a series of steps. To avoid further confusion,
we still used γM G and γGY to denote the DNA-gene association and gene-phenotype
association. For i-th subject, five factors (fi ) were first simulated based on the
underlying CpG site (Mi1 ) from the equation,
fi = Mi1 γM G + XiT γXG + ϵi1 ,

(2.8)

where γM G is the vector of DNA-gene associations, ϵi1 ∼ N (0, I) were normal, and
the the covariate coefficients γXG were set equal to 0.5. Second, Yi was generated
based on the latent factors from the equation,
Yi = γ0Y + fiT γGY + XiT γXY + ϵi2 ,

(2.9)

where ϵi2 ∼ N (0, 1) is the error term, γGY is the vector the gene-phenotype associations. γXY and γ0Y were set to the same values as the low-dimensional cases.
In the last step, the gene expression data (Gi ) were generated based on the factors
(fi ), the error term (Ui ∼ N (0, I)), and the loading matrix (B) following Baek et al.
(2020). We formed B =

√1 LT E
n

where L ∼ N (0, I) and E is an n × k orthogonal

matrix formulated by the eigenvectors corresponding to the k largest eigenvalues
of LLT . The optimal k can be estimated by minimizing the cross-validated mean
squared error (MSE), as suggested by Owen and Perry (2009).
After deriving the latent gene factors via factor analysis (Baek et al., 2020), pIG
j
was derived according to Equation (2.1) and Equation (2) by using fi instead of
Gi to implement the proposed methods. Next, we reported the empirical power
of the underlying CpG site with methylation for γM G ranging from 0 to 0.5. The
gene-phenotype association γGY was set equal to 0.1, 0.2, and 0.5, and the missing
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rate was 70%. Notably, in the high-dimensional case, multiple imputation becomes
computationally infeasible.

2.4.4

Competing Methods

Four competing methods were considered in the simulation studies: (1) complete
case studies using only the complete set with the integrative analytical framework
(Zhao et al., 2014), (2) KNN imputation algorithm (Batista et al., 2002) to estimate
the missing values using the mean of the nearest values of k-th closest subjects,
(3) multivariate imputation via chained equations (MICE) method to estimate the
missing values by combining results derived from multiple imputed datasets, and
(4) linear model on all subjects of M and Y . In (2) and (3), the IG model was
implemented to identify the underlying CpG site after imputing the missing values
in the gene expression data.
We implemented a 10 nearest-neighbor imputation method with the impute package (Hastie T and G, 2021) and applied the MICE algorithm with the mice package
(van Buuren et al., 2021) in R. The maximum number of iterations was set equal to
5 in MICE and 5 datasets were generated for pooling results. Due to the intractable
computational time in the high-dimensional case, MICE was not implemented in
Scenario III.

2.4.5

Simulation Results

Table 2.1 reports the FWER and the FDR of testing the CpG sites with γM G =
γGY = 0 (no association with the outcome Y ). The results show that our proposed
methods and the existing method maintained FWER and FDR at the nominal 0.05
level.
Figure 2.2 presents the average power of the proposed omnibus method and the
competing methods to compare the performance for identifying the underlying CpG
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Table 2.1. Table for FWER after weighted Bonferroni method and FDR after
weighted BH method when all associations were set equal to 0.

20%
50%
70%

IG
FWER 0.037
FDR 0.037
FWER 0.063
FDR 0.062
FWER 0.028
FDR 0.031

MICE
0.010
0.010
0.013
0.013
0.026
0.027

KNN General
Impute Weight
0.045
0.037
0.052
0.037
0.061
0.061
0.061
0.062
0.044
0.027
0.050
0.030

Reverse
Weight
0.048
0.049
0.060
0.059
0.045
0.040

Omnibus
Method
0.047
0.053
0.065
0.077
0.048
0.054

Linear
Model
0.053
0.057
0.053
0.057
0.053
0.057

site. In datasets with a high missing rate (≥ 50%), the proposed omnibus method is
more powerful than the IG model with a complete case approach and the imputation
algorithms. For example, when the missing rate is 70% and γM G = γGY = 0.2, the
proposed omnibus method achieves the highest power, which is 10.5% higher than
the IG model and 52.3% higher than MICE.
Figure 2.3 presents the performance using the general weighting scheme, the reverse weighting scheme, and the omnibus method. Based on our simulation results,
the general weighting scheme performes better in datasets with a low missing rate
while the reverse weighting scheme performs better with a high missing rate (> 50%)
as well as a large γGY (e.g. γGY = 0.5). We set λ in the ACAT test statistic in
terms of the missing rate as described in Section 2.3.3. Our results show that the
proposed omnibus method demonstrates a more competitive performance compared
to the other methods.
The performance of our proposed method in a high-dimensional case is illustrated
in Figure 2.4. In this scenario, the missing rate was set equal to 70% to mimic that
of the experimental dataset used in this chapter. As shown in the power plots, the
omnibus method is more powerful than the IG in all cases except when γM G and
γGY are extremely weak. The proposed method outperforms the other competing
methods when the gene-phenotype signal is moderate γGY = 0.2 but is comparable
to the linear model when γGY = 0.5.
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Figure 2.2. Power comparisons of omnibus method, MICE, KNN imputation, IG
and linear model for various missing rates and γM G . The value of γGY was set equal
to 0.1, 0.2 and 0.5. The standard deviations of both γM G and γGY were set equal to
1.
In consideration of the case where the missingness is explained by observed variables, we further conducted simulation studies for a missing at random case. Table 2.2
reports the FWER and FDR of testing the CpG sites with γM G = γGY = 0 after the
weighted bonferroni method and q-value method as described in Section 2.4.1. The
results show that all the methods maintain both the FWER and the FDR at the
nominal 0.05 level.
Figure 2.5 and Figure 2.6 present the power comparisons of the proposed omnibus
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Figure 2.3. Power comparisons of omnibus method, general weight scheme, reverse
weight scheme, IG and linear model for various γM G and γGY with different missing
rates.

Figure 2.4. Power curves for omnibus method and competing methods in highdimensional case. The number of factors k = 5 was determined by the 10-fold crossvalidation. The gene-phenotype association γGY was set to be 0.1, 0.2 and 0.5.
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Table 2.2. Type I error control for FWER using weighted Bonferroni method and
FDR using q-value method when γM G = γGY = 0 under MAR.

20%
50%
70%

IG
FWER 0.047
FDR 0.044
FWER 0.051
FDR 0.053
FWER 0.048
FDR 0.051

MICE
0.007
0.007
0.020
0.021
0.022
0.024

KNN General
Impute Weight
0.051
0.046
0.058
0.044
0.047
0.051
0.051
0.054
0.058
0.048
0.060
0.051

Reverse
Weight
0.058
0.055
0.037
0.041
0.055
0.052

Omnibus
Method
0.054
0.064
0.042
0.051
0.068
0.081

Linear
Model
0.055
0.058
0.050
0.052
0.056
0.055

method to existing methods (MICE, KNN, IG, and LM) and the component methods
(general and the reverse weighting schemes) under MAR for identifying the underlying CpG site. The results are similar to the MCAR case in Section 2.4.2, which
demonstrates that our proposed methods outperform the other methods.
Figure 2.7 presents the performance of our proposed method in the high-dimensional
case. As shown in the power plots, the omnibus method with the circled line is more
powerful than the IG in all cases except when the signals of γM G and γGY are weak.

2.5

Experimental Data Analysis

We implemented our proposed omnibus weighting approach using the preterm infant
data described in section 2.2. The infants birth weight scores were used as the phenotypic outcome (Y ). The weight scores were calculated by the normal quantile of
the birth weights for each gestational age in the entire population of newborn infants
so that they are normally distributed, as described in the Japanese reference data
(Kashima et al., 2021; Agha et al., 2016; Oken et al., 2003). According to Kashima
et al. (2021), the methylation levels (M ) were measured by β values ranging from
0 (completely unmethylated) to 1 (completely methylated) to indicate the intensity
of methylation on each CpG site. Both the methylation levels and the birth weight
scores were scaled to have a mean of 0 and a variance of 1.
The clinical covariates considered in this analysis included paternal age, maternal
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Figure 2.5. Power comparisons of omnibus method, MICE, KNN imputation, IG
and linear model for various missing rates and γM G under MAR. The value of γGY
was set equal to 0.1, 0.2 and 0.5. The standard deviations of both γM G and γGY were
set equal to 1.
age, paternal body mass index (BMI), maternal BMI, maternal smoking status before
pregnancy, and the gender of the infants. To correct for population stratification, we
implemented surrogate variable analysis (SVA) (Leek and Storey, 2007) to account
for the unobserved effect from the clinical covariates. The genomic inflation factor
(van Iterson et al., 2017) was used after SVA for adjusting the inflated p-values due
to population stratification. Figure 2.8 presents the QQ-plot for omnibus method
and suggests proper type I error control.
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Figure 2.6. Power comparisons of omnibus method, general weighting scheme,
reverse weighting scheme, IG and linear model for various γM G and γGY with different
missing rates under MAR. The standard deviations of γM G and γGY were both set
equal to 1.

Figure 2.7. Power curves for omnibus method and competing methods in highdimensional case under MAR. The number of factors k = 5 was determined by the
10-fold cross-validation. The value of γGY was set to be 0.1, 0.2 and 0.5.
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Figure 2.8. QQ-plots for p-values after SVA and genomic inflation factor adjustment
for the proposed omnibus method.
As discussed in section 2.2, data was collected from 157 participants. However,
mRNA gene expression measurements were only available for 55 participants. In
the complete data set, after standardizing the mRNA expression measurements, we
implemented the factor analysis as described in section 2.4.3 for 46,789 mRNA expression measurements. The optimal number of factors (k = 7) was determined by
minimizing the Wold-style 10-fold cross-validated MSE (Owen and Perry, 2009).
For 410,735 CpG sites, we implemented our proposed weighting schemes one CpG
site at a time to derive the weighted p-values for identifying the association with
infant birth weights. The weighted p-values for all CpG sites with the corresponding
chromosomes are presented in Figure 4. The number of significant CpG sites are
provided in Web Appendix C. As presented in Web Table 2, none of the CpG sites
were identified as significant in either q-value method or the weighted Bonferroni
method after implementing our proposed omnibus method.
The top 30 CpG sites are listed in Table 2.3 with the corresponding reference
sequence (RefSeq) gene symbols. The CpG sites are listed in the ascending order
of p-values derived from the omnibus method after SVA and the genomic inflation
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Figure 2.9. Plot for percentage of variance explained by the principal components
(PC) over the number of PC. The first 10 principal components explain 97.9% of the
variance of gene expression data.
factor adjustment. As shown in Table 2.3, PIM1 is the gene that the second most
significant CpG site is located on. PIM1 was found to be expressed in B-lymphoid
and myeloid cells and the methylation of cg25325512 (PIM1 ) mediates the effect of
maternal smoking on the birth weight of infants (Witt et al., 2018).

2.6

Discussion

In this chapter, we propose a novel framework to implement integrative analysis for
multi-omics data where the intermediate variables, such as mRNA gene expression
measurements, are completely missing for a large proportion of subjects. Existing
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Table 2.3. Top table for 30 CpG sites associated with birth weight scores of
preterm infants with the smallest weighted p-values derived from the proposed omnibus method. Chromosomes, CpG sites, UCSC RefSeq gene names, weighted pvalues and q-values are reported. The results were adjusted for paternal age, maternal
age, paternal BMI, maternal BMI, maternal smoking status before pregnancy, and
the gender of infants.
Rank
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

Chromosome
2
6
2
2
3
2
2
2
3
2
11
7
18
11
5
7
6
1
2
12
14
2
5
6
11
1
19
6
3
2

CpG site
Gene name Weighted p-value q-value
cg10855531
6.52e-07
0.199
cg25325512
PIM1
9.70e-07
0.199
cg20219891
2.84e-06
0.324
cg13872898
3.16e-06
0.324
cg25773386
GPR62
6.85e-06
0.428
cg00637745
7.29e-06
0.428
cg14311362
7.30e-06
0.428
cg07133097
9.30e-06
0.45
cg08120226
MUC4
9.96e-06
0.45
cg17870997
1.10e-05
0.45
cg08162803
TCIRG1
1.28e-05
0.479
cg18158419
FIS1
1.78e-05
0.533
cg15871086
1.81e-05
0.533
cg13746740
1.82e-05
0.533
cg25368647
MXD3
1.97e-05
0.538
cg06557644
NOD1
2.76e-05
0.708
cg16199747
2.94e-05
0.711
cg23305408 COL16A1
3.74e-05
0.79
cg17979068
C2orf48
3.75e-05
0.79
cg21052873
NCOR2
3.85e-05
0.79
cg07159958
ATL1
4.61e-05
0.829
cg02100410 LOC151534
4.66e-05
0.829
cg05992340
PDE4D
5.17e-05
0.829
cg13892322
LY6G5C
5.28e-05
0.829
cg10469774
5.36e-05
0.829
cg12723026
KCNC4
5.50e-05
0.829
cg24449014
MEGF8
5.61e-05
0.829
cg21457401
PNLDC1
5.69e-05
0.829
cg13268590
MAGI1
5.99e-05
0.829
cg02640173
GLI2
6.05e-05
0.829
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multi-omics integrative studies require removing missing records or applying data
imputation techniques to prepare a complete dataset for the analysis. However, when
the missing rate is high, especially higher than 50%, the power of complete case
analyses and imputation methods decreases drastically due to the reduction in sample
size. Our proposed framework utilizes a p-value weighted adjustment and hence
incorporates information from both complete and incomplete observations in the data.
The advantages of implementing the proposed framework in the multi-omics integrative analysis are multifold. First, by incorporating the information from incomplete observations, our proposed approaches boost the power of multi-omics integrative analyses compared to the existing methods. Second, our proposed approaches
perform well even in situations with a large missing proportion of intermediate variables. Third, the two component weighting schemes combined in the omnibus test
can provide flexibility in the implementation of multi-omics integrative analyses with
missing rates ranging from 0 to 1. Furthermore, our simulation analyses showed that
the proposed method maintains proper FWER control with the weighted bonferroni
method and FDR control with the q-value method. According to Storey et al. (Storey
and Tibshirani, 2003; Storey et al., 2004), the utilization of q-value method can also
maintain FDR even with weak dependence structures between CpG sites. In addition, the proposed method can be implemented in a computationally efficient manner
because the weights can be easily computed.
In our proposed method, the two component weighting schemes perform differently in datasets with various missing rates. According to section 2.4.5, the general
weighting scheme achieves greater power in cases where the missing rates are lower
than 50% while the reverse weighting scheme achieves better performance when the
missing rates are high. A possible strategy to utilize the advantages of both methods
is to set a dynamic contribution constant in terms of the missing rate in the omnibus
test to up-weight the general scheme in situations where the missing rate is low and
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emphasize the reverse scheme when the missing rate is high. The simulation studies
show that the proposed omnibus method demonstrates more competitive results in
both low and high missing rate situations. However, our proposed method can only
be applied to datasets with missing records in the intermediate variables of the multiomics integrative analysis. When phenotypic outcomes or independent variables are
also missing, methods such as data imputations could be considered.
We implemented the proposed method in a birth weight study of preterm infants
and identified the CpG sites with DNA methylation that are associated with birth
weights of preterm infants via the regulation of gene expression. In practice, our analytical framework can be directly applied to any continuous independent variables
(such as DNA methylation levels), or discrete variables (such as SNP genotypes or
DNA mutation status). Since the measurements were of intensity values generated
via microarray experiments, we assumed that the intermediate variables followed
normal distributions. However, if the intermediate measurements are generated by
high-throughput RNA sequencing (RNAseq), preprocessing procedures such as normalization by the sequencing depth and log transformation of the data, as described
in the limma (Cloonan et al., 2008) or voom (Law et al., 2014), could be applied for
ensuring normality before implementing the weighting schemes.
As discussed in sections 2.3 and 2.5, the implementation of SVD-based dimension
reduction techniques allows us to apply our integrative framework to datasets with
high-dimensional intermediate variables. Other variable selection approaches such as
LASSO could also be used to reduce the dimension of mRNA gene expression in the
analysis. Another future research area is the Cox model for survival outcomes in
the integrative framework. Applying the Cox regression in our proposed integrative
framework would require the implementation of estimating equation theory and to
derive the asymptotic distribution of the estimates (Zhao et al., 2014). Therefore,
further work is needed to develop multi-omics integration frameworks for survival
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outcomes.
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Chapter 3
Identification of dynamic gene co-expression
via Bayesian variable selection
3.1

Introduction

A wealth of gene expression data generated by high-throughput techniques provide
exciting opportunities for studying genetic interactions systemically. Genetic interactions in a biological system are tightly regulated and are often highly dynamic. The
interactions can change flexibly under various internal cellular signals or external
stimuli. Previous studies have developed statistical methods to examine these dynamic changes in genetic interactions. However, a common challenge encountered in
the existing approaches is the computational intensiveness due to the massive amount
of gene combinations needed to be considered in a typical genomic dataset, and yet
often a much smaller proportion of gene interactions exhibit dynamic co-expression
changes.
To solve this problem, we propose variable selection methods in Bayesian frameworks with spike-and-slab priors. The proposed algorithms focus on subsets of promising gene combinations in the search space. We also adopt a Bayesian false discovery
control procedure for testing the significance of dynamic gene co-expression changes.
Simulation studies are conducted comparing our proposed approaches to existing
exhaustive search heuristics. We demonstrate the implementation of our proposed
approaches in experimental data analysis to study gene co-expression changes associated with colorectal cancer recurrence-free survival.
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In this chapter, we set out to identify dynamic gene co-expression (DC) patterns
that are associated with cancer recurrence risk. Previous studies of cancer recurrence
risk mainly focused on one-dimensional gene expression levels (Mallmann et al., 2010;
Pan et al., 2019; Shi et al., 2017). Depicting dynamic joint gene co-expression patterns
would offer new insights into the mechanisms of cancer recurrence and provide new
biomarkers for treatment selection and prognosis prediction.
This chapter is structured as follows. Section 3.2 provides an overview of the
dataset and Section 3.3 introduces the proposed models as well as the estimation
approaches of the proposed spike-and-slab model. Section 3.4 presents two simulation
studies with different degrees of sparsity in the search space. Section 3.5 demonstrates
the implementation of our proposed approaches with the experimental data analysis
on a colorectal cancer (CRC) dataset. In section 3.6, we provide discussions and
suggestions for future research on these topics.

3.2

Datasets and Databases

The CRC dataset used in this chapter is based on the study by Smith et al. (2010)
available in Gene Expression Omnibus with accession number GSE17536. This study
included data from 177 CRC patients, and gene expression levels for 54,675 transcripts
were measured using Affymetrix Human Genome U133 Plus 2.0 (hgu133plus2) platform. For identifying DC gene pairs associated with recurrence-free survival, 20,186
genes with unique gene symbols were selected. We excluded the participants who
dropped out at the beginning of the study and use the remaining 145 records in the
experimental data analysis. The cancer recurrence-free survival time was defined as
the length of time that CRC patients live without cancer recurrence after the surgery.
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3.3

Model

Let Xi = (Xi,1 , ..., Xi,q )T be the vector of q gene expression levels of the i-th participant, i = 1, ..., n, with each following a standard normal distribution. The vector of
the pair-wise products of Xi is denoted as Yi = (Yi,1 , ..., Yi,m )T = (Xi,1 · Xi,2 , Xi,1 ·
Xi,3 , ..., Xi,q−1 ·Xi,q )T . In j-th pair of gene combinations, j = 1, ..., m, the pair of genes
used to calculate the product can be denoted as Xi,j1 and Xi,j2 , 1 ≤ j1 < j2 ≤ q. For
a set of q genes, the total number of gene-pair combinations is m =

 
q
2

. In practice,

q could be around 20,000 and m ≈ 2 × 108 as demonstrated in the experimental data
analysis.
Let zi be the modulating factor, which represents the recurrence-free survival time
for the i-th participant. As discussed in section 3.1, DC can be demonstrated using the conditional expectation of the product of two gene expression levels given
the modulating factor if the two genes are standard normal (Li, 2002), that is,
ρ(Xi,j1 , Xi,j2 | zi ) = E(Xi,j1 Xi,j2 | zi ). Based on the normality assumption for Xi ,
the product vector of the expression levels Yi can be used as the measurement of the
gene co-expression to formulate the model of DC.
Nadarajah and Pogány (2016) derived the probability density function for the
product of two standard normal gene expression levels, Yi,j | ρi,j ∼ N P(ρi,j ), with ρi,j
presenting the correlation coefficient between j-th pair of genes for i-th participant.
The distribution has the following formulation,
1

e
f (Yi,j = yi,j | ρi,j ) = q
π 1 − ρ2i,j

ρi,j yi,j
1−ρ2
i,j

K0

|yi,j |
1 − ρ2i,j

!

,

(3.1)

with K0 (·) being the second class zero-order modified Bessel function, and E(Yi,j ) =
ρi,j . Next, we consider a general form of DC between the modulating factor and the
co-expression of the gene pairs (Ho et al., 2011; Kinzy et al., 2019; Yang and Ho,
2021),
g(ρi,j ) = g(ρ(Xi,j1 , Xi,j2 | zi )) = τ0,j + τ1,j × zi ,
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(3.2)

where g(·) =

1
2

log



1+(·)
1−(·)



is the Fisher’s Z-transformation to ensure that ρi,j falls

within (-1,1). Considering the inverse function of the Fisher’s Z-transformation,
g −1 (·) =

e2(·) −1
,
e2(·) +1

DC between j-th pair of genes has the following form, ρ(Xi,j1 , Xi,j2 |

zi ) = E(Xi,j1 Xi,j2 | zi ) = E(Yi,j | zi ) = g −1 (τ0,j + τ1,j zi ). Our goal is to estimate τ1,j
to quantify DC with respect to the modulating factor zi . Thus the DC model can be
formulated as follows,
ind

Yi,j | τ0,j , τ1,j , zi ∼ N P{g −1 (τ0,j + τ1,j zi )},

(3.3)

In Equation (3.3), τ1,j is the main parameter of interest and represents the strength
of association between z and the correlation between j-th pair of genes. A positive τ1,j
suggests that the increasing positive correlation is associated with longer recurrencefree survival time. When τ1,j = 0, the correlation of gene pair j is not associated with
the recurrence-free survival time. The intercept τ0,j is the Fisher’s Z-transformed
correlation coefficient between j-th pair of genes when the patient’s colorectal cancer
recurrence-free survival time is 0.
To develop the variable selection models in a Bayesian framework, we need to
specify the prior distributions for model parameters. The prior for τ0,j can be set
to N (0, 1). Theoretically, the approximate variance of Fisher’s Z-transformation is
1
,
n−3

with n presenting the sample size (Fisher et al., 1921). The N (0, 1) prior for

τ0,j yields sufficiently large variance and performs well in our simulation analyses as
described in Section 3.4. The prior distributions for τ1,j are the cores in the structure
of the variable selection models proposed in this chapter, which will be discussed
next.
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3.3.1

SPSL model

To effectively identify the dynamic gene co-expression within sparse DC signals, we
consider the continuous spike-and-slab prior (Ishwaran et al., 2005) for τ1,j as follows,
ind

τ1,j | γj , vj2 ∼ N (0, γj vj2 ),
i.i.d.

vj2 | α1 , α2 ∼ IG(α1 , α2 ),

(3.4)

ind

γj | wj ∼ wj I1 + (1 − wj )Iv0 ,
i.i.d.

wj ∼ U(0, 1).
In this model framework, the variance of the prior distribution for τ1,j is the
product of two parameters γj and vj2 . The prior of the γj is a mixture of two point mass
measures, and vj2 has an inverse gamma prior with shape and scale hyperparameters
α1 = 5 and α2 = 50 (mean is 12.5). Figure 3.1 illustrates the shapes of the conditional
densities for the bimodal inverse gamma distributions (γj vj2 ) with different values for
wj and v0 . The extent of shrinkage of τ1,j toward 0 is controlled by the selection
variable wj . A small value of wj leads to more shrinkage. We set v0 = 0.005 in our
analyses following Ishwaran et al. (2005).

3.3.2

C-SPSL model

Consider the fact that genetic interactions can be modulated by same factors, the
shrinking of different gene-pair combinations can not be entirely independent (Lee
et al., 2017). Therefore, we further develop a correlated spike-and-slab model (CSPSL) to incorporate the dependencies among selection parameters w. Instead of
assigning independent uniform priors for w, we take the idea of assuming a global
prior for the probabilities of shrinking to derive dependent posterior distributions of
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Figure 3.1. Conditional density plots for the bimodal inverse gamma distributions
with α1 = 5 and α2 = 50. Plot (a) and (b) present the different shapes of the densities
with w = 0.2 and w = 0.95 respectively while fixing v0 = 0.005. Plot (c) and (d) are
generated with fixing v0 = 0.08 and varied w = 0.2 and w = 0.95 respectively.

w. The structure of C-SPSL model is described as follows:
ind

τ1,j | γj , vj2 ∼ N (0, γj vj2 )
i.i.d.

vj2 | α1 , α2 ∼ IG(α1 , α2 ),
ind

γj | wj ∼ wj I1 + (1 − wj )Iv0

(3.5)

i.i.d.

wj | c ∼ Beta(c, 1 − c),
c ∼ U(0, 1),
In Equation (3.5), w is set with priors of the beta distributions with a global hyperparameter c instead of independent standard uniform priors. The global hyperparameter
c allows the marginal distributions of w to be correlated. The priors for τ0,j , vj2 , γj
and the settings of hyperparameters v0 , α1 and α2 are the same as in the SPSL model.
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3.3.3

Estimation

Let θ denote the vector of all the parameters. The likelihood function of θ is given
by
L(θ | Y, z) =

n Y
m
Y

f (Yi,j | zi , θ),

(3.6)

i=1 j=1

where f (·) is the density function of Yi,j given in Equation (3.3). The posterior joint
distribution for θ with prior π(θ) can be described as
π(θ | Y, z) ∝

n Y
m
Y

f (Yi,j | zi , θ) × π(θ).

(3.7)

i=1 j=1

The main difference between the SPSL model and the C-SPSL model is the prior
distribution of wj . The full conditional distributions involved in the posterior computation are derived and sketched in Web Appendix A.
In order to develop an efficient Markov Chain Monte Carlo (MCMC) algorithm,
we implement the adaptive Metropolis algorithm (Haario et al., 2001). Different multivariate normal distributions are used as the proposal distributions in our algorithm
to maintain an acceptance rate close to 20-30%. The details of the adaptive algorithm
and operation process are provided in Web Appendix B.

3.3.4

Hypothesis Testing

To declare significant τ1,j , we implement the following hypothesis testing procedure.
Because the distributions of τ1,j are continuous and hence P (τ1,j = 0) = 0, a small
value ϵ > 0 is used to define the local null and alternative hypotheses. For j-th pair
of genes, the local hypotheses are defined as, H0j : |τ1,j | < ϵ vs. Haj : |τ1,j | ≥ ϵ, j =
1, ..., m. In practice, The value of ϵ can be determined based on expert knowledge as
illustrated in our experimental data analysis (section 3.5). With the MCMC samples,
we can calculate the posterior probability of the local null hypothesis,
h
1X
1 (l) ,
P(H0j | Data) =
h l=1 (|τ̃1,j |<ϵ)
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(3.8)

(l)

where h is the number of iterations after the burn-in period and τ̃1,j is the sample of
τ1,j at the l-th iteration after the burn-in period. The local alternative hypothesis is
defined as P(Haj | Data) = 1 − P(H0j | Data).
We propose to use Bayes factor to assess the degree of evidence in favor of the
alternative hypothesis. Unlike using the posterior probability of the alternative hypothesis, using Bayes factor will balance out the effect of the prior by taking into
account the prior probabilities of the hypotheses. Specifically, the Bayes factor of the
alternative hypothesis for the j-th local hypothesis test is defined as follows,
P (Haj |Data)
P (H0j |Data)
,
P (Haj )
P (H0j )

BFj =

where P (H0j ) and P (Haj ) represent the prior probabilities of local null and alternative hypotheses respectively. We reject the null hypothesis H0j and claim the j-th
gene pair is significant if BFj is greater than some critical value r. In the Bayesian
literature, taking r = 3 and 10 represents substantial and strong evidence of favoring
the alternative hypothesis, respectively.
Considering the large number of local hypotheses tests in our study, multiplicity
has to be addressed to avoid an inflated false positive rate (FDR). For this purpose, a
Bayesian multiple testing procedure proposed by Müller et al. (2004) and Wang and
Dunson (2010) is applied to control the expected false discovery rate. As suggested
by Wang and Dunson (2010), the expected false discovery rate (FDR) is defined as a
function of r in the following form,
P

FDR(r) =

j

1(BFj ≥r) (1 − δj )
,
j 1(BFj ≥r) + e

P

where δj = P(Haj | Data) is the posterior probability of the local alternative hypothesis Haj and e is a small positive value (e.g. 0.0001) that prevents the denominator
from being zero. By controlling the FDR at the pre-specified significance level α, we
can determine the optimal critical value: ropt = min
{r ∈ [0, +∞) : FDR(r) ≤ α}
r
and reject H0j if BFj > ropt for each j.
39

3.4

Simulation

In this section, we assessed the performance of the proposed DC variable selection
models in a Bayesian framework and compared them with a competing approach via
implementing simulation studies. The simulated data sets were generated under two
scenarios with different degrees of sparsity as well as different dimensions of search
space.

3.4.1

Settings

In the first simulation scenario, we compared our proposed models (SPSL and CSPSL) to the conditional normal model (Ho et al., 2011; Kinzy et al., 2019) in a
Bayesian framework. The competing method assumed each gene pair to be a bivariate
normal distribution while allowing the modulating factors to have an arbitrary distribution. Comparing to our proposed models, the conditional normal model used an
exhaustive search strategy to implement a genome-scale scan for all possible gene-pair
combinations without handling the sparsity. To present the difference between our
proposed approaches and the competing method, we named the competing method
as exhaustive search method (ES).
We set a small number of gene-pair combinations and moderately sparse DC
signals in this scenario with 5 genes (q = 5), resulting in 10 genes pairs (m = 10).
The vector of main parameters τ1 was set to be (0, 0, 0, 0, 0, 0, 0, 1, 1, 1)T , where 70%
of the values were zero so that the sparsity in this scenario was 70%.
In the second scenario, we considered a larger number of gene-pair combinations
to evaluate the performance of our proposed models in large search space with highly
sparse DC signals. In this simulation, 50 genes (q = 50) and hence 1,225 gene-pair
combinations (m = 1, 225) were generated. In the vector of τ1 , only 10 gene pairs
were set with τ1,j = 1 and all other pairs were 0 so that the sparsity indicated by
the proportion of zero values is 99.18%. As discussed in section 3.1, however, the
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ES method quickly became computational intractable as the number of gene-pair
combinations increased. In this scenario, the ES method was inapplicable due to the
astronomical computational time under the same number of iterations and chains
of MCMC as the proposed methods. We therefore only presented the results of the
proposed models in this case. The true values of the intercepts τ0 = (τ0,1 , ..., τ0,m )T
were all set equal to zero in both scenarios.
The simulation data were generated in the same procedures in both scenarios.
For observation i, we first simulated the covariate zi from U(0, 1) which represented
the recurrence-free survival time. The correlation ρi,j between the j-th pair of gene
Xi,j1 and Xi,j2 , 1 ≤ j1 < j2 ≤ q, was then calculated using Equation (3.2). Next,
the covariance matrix Σi for all genes can be constructed as follows, Σi = cov(Xi ),
where cov(Xi,j1 , Xi,j2 ) = 1 if j1 = j2 , and cov(Xi,j1 , Xi,j2 ) = cov(Xi,j2 , Xi,j1 ) = ρi,j
if j1 ̸= j2 . After deriving the covariance matrix, the gene expression vector Xi was
generated from a multivariate normal distribution, Xi ∼ Nq (0, Σi ). It was noted that
the marginal distributions of Xi were all standard normal distributions due to unit
diagonal elements in Σi . In the last step, we obtained Yi by taking pairwise products
of the gene expression vector Xi .
For hypothesis testing, the value of ϵ was set equal to 0.2 in the first scenario
(moderately sparse case), and 0.5 in the second scenario (highly sparse case). Since
the true statuses of the hypotheses were known in the simulation, the empirical false
discovery rate (FDR), false negative rate (FNR) can be calculated based on the
threshold of the Bayes factor described in Section 3.3.4:
P

j

FDR =

0 =0)
1(BFj ≥ropt ) × 1(τ1,j

P

j

P

FNR =

j

1(BFj ≥ropt ) + e

0 ̸=0)
1(BFj <ropt ) × 1(τ1,j

P

j

1(BFj <ropt ) + e

,

(3.9)

,

(3.10)

0
where ropt is the optimal criterion that is determined by controlling the FDR and τ1,j

is the true value of dynamic gene co-expression for the j-th pair of gene combinations.
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3.4.2

Results

The adaptive MCMC procedures were implemented to estimate the parameters in
SPSL and C-SPSL models. We set the number of iterations to be 20,000 with a
burn-in period of 10,000 iterations. To evaluate the convergence of MCMC sampling,
we implemented the Gelman-Rubin convergence diagnostics (Gelman et al., 1992)
on three chains by comparing the between-chains and within-chains variances. As
suggested by Brooks and Gelman (1998), a criterion of the diagnostic statistics being less than 1.2 for all parameters indicated convergence for MCMC samples. As
presented in diagnostic results (Web Appendix D), the Gelman-Rubin statistics were
close to 1 for all τ1,j and the tracing plots are mixed well. The results indicate good
convergence for both SPSL and C-SPSL. All simulations were implemented on the
Intel(R) Xeon(R) CPU @ 2.40GHz processors.
Table 3.1 presents FDR and FNR for our proposed approaches and the ES method
with different sample sizes, 200, 500, and 1,000. The proposed approaches have lower
FDR than ES, while the FNR of the proposed models is slightly higher when the
sample sizes are small. As the sample size increases to 1,000, the FNR of both SPSL
and C-SPSL decreases to 0 while still maintaining a smaller FDR than ES.
Table 3.1. Comparison of ES, SPSL and C-SPSL model based on 100 simulation iterations in scenario I (sparsity = 70%). The true values of τ1 are set to be
(0, 0, 0, 0, 0, 0, 0, 1, 1, 1)T and the true values τ0 are set to 0. The false discovery rate
(FDR) and false negative rate (FNR) are reported.
Sample size
n = 200

n = 500

n = 1, 000

Method
ES
SPSL
C-SPSL
ES
SPSL
C-SPSL
ES
SPSL
C-SPSL
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FDR
0.1790
0.0200
0.0108
0.0530
0.0150
0.0100
0.0175
0.0025
0.0025

FNR
0.0067
0.0652
0.0903
0.0000
0.0012
0.0012
0.0000
0.0000
0.0000

To further compare the efficiency of SPSL and C-SPSL, we performed a second
simulation study with 50 genes and 1,225 gene-pair combinations with highly sparse
signals. It was impractical to implement ES in this scenario due to the computational
intensiveness, and only the two proposed approaches were implemented. In Table 3.2,
the C-SPSL are preferable as FDR and FNR are both much smaller.
Table 3.2. Comparison of SPSL and C-SPSL model based on 100 simulation iterations in scenario II with with 1,225 gene pairs. The true values of τ1 = 0 except for
10 gene pairs τ1 = 1 (sparsity=99.2%). The true values of τ0 are set to be all 0. The
false discovery rate (FDR) and false negative rate (FNR) are reported.
SPSL
C-SPSL

3.5

FDR
FNR
0.0306 0.0055
0.0197 0.0042

Experimental Data Analysis

In this section, we implemented the proposed C-SPSL model to identify gene pairs
with significant non-zero τ1,j (DC gene pairs) associated with the recurrence-free survival time. In the CRC dataset considered in this study, a total number of 2.04 × 108
gene-pair combinations needed to be considered with the 20,186 unique gene expression measurements. A screening measure ζj = Cor(|Xj1 |, |Xj2 |) − |Cor(Xj1 , Xj2 )| was
applied to identify 949,280 (≈ 106 ) gene pairs that potentially exhibit DC patterns
(Yu, 2018), where j1 and j2 represent the two genes for j-th pair. After the screening
step, we chose to implement C-SPSL on all 949,280 gene pairs because it performed
slightly better than SPSL in the highly sparse situation considered in this experimental data analysis. To improve the computational efficiency, we used computer
clusters to separate all selected gene pairs into 1,000 groups with each including 950
pairs and apply the C-SPSL model for each group parallelly.
We used individual patients’ recurrence-free survival time (z) to indicate their
ability to survive without CRC recurrence or metastasis after the surgery. If the
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recurrence-free survival time of i-th observation was right-censored, the predicted
value E(Ti | Ti > t0i ) was used, with Ti representing the CRC recurrence-free survival
time and t0,i representing the censoring time for observation i. The calculation of
E(Ti | Ti > t0,i ) was described in Web Appendix E. Finally, the recurrence-free
survival time estimates were re-scaled by their maximum value in the CRC dataset
so that all z were within (0, 1].
The parameters in the C-SPSL model qwre estimated using the adaptive MCMC
algorithm with 20,000 iterations and 10,000 burn-in. As described in Section 3.3.4,
The hypothesis testing procedure was implemented to identify gene pairs with significant DC signals. We set ϵ = 0.5 in the local hypotheses as presented in Equation (3.8).
By controlling the FDR at 0.05 level, 2,570 gene pairs were identified to be statistically significant. The DC signals in the CRC dataset can be considered as highly
2,570
sparse ( 949,280
≈ 0.3%). The empirical distribution of τb1 (the posterior mean of τ1 )

based on all 949, 280 gene-pair combinations was presented in Web Figure 1. It was
observed that the proportion of |τb1 | being greater than 0.5 is 0.023.
The top 30 gene pairs with the largest posterior mean |τb1 | from the CRC dataset
are listed in Table 3.3. The trace plots and the Gelman-Rubin diagnostic results for
the top |τb1,j | are provided in Web Appendix D.
To visualize the DC patterns, the profile plots of the top two gene pairs are
presented in Figure 3.2 with the recurrence-free survival time (z) binned into 3quantiles. Among all the gene pairs, MEP1B and C18orf12 have the largest τb1 =
2.981 associated with the recurrence-free survival time. The meprin β (MEP1B) was
found to be positively correlated with the colorectal cancer survival prognosis (Peters
and Becker-Pauly, 2019). Although the function of C18orf12 -encoded protein has
not been fully characterized, our analysis reports the positive τ1 estimate between
MEP1B and C18orf12 with the colorectal cancer recurrence-free survival time. Our
results suggest patients with a larger correlation between MEP1B and C18orf12 gene
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Table 3.3. The top 30 significant gene pairs with the largest posterior mean |τb1 |
associated with recurrence-free survival time. The 95% posterior credible intervals
(95% CI) for each parameter are provided in the parentheses.
j
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

Gene I
C18orf12
SCEL
POLR3A
MEP1B
PRR16
LOC642696
METTL6
ZMYM2
PIK3CA
KIF19
KCNS1
LINC01013
LOC100129175
PIK3CA
FMN2
SCGB1D2
C16orf74
LOC389199
MYH7B
PLEK
FILIP1L
LOC101928760
MYH7B
LOC101928553
KCNIP2
MEP1B
C11orf42
FAM218A
LOC101928760
LINC00889

Gene II
MEP1B
TGIF1
MEP1B
MIR4500HG
PLAU
DDX25
MEP1B
AMELX
PIP
LOC105379426
TEX48
SMYD1
ZNF787
SCGB1D1
SH2B1
SNHG10
TBC1D21
MYH7B
UCP1
AQP9
GDPD1
TMEM151B
ADARB2
SPINT3
MLANA
NIPAL3
SNHG10
DIPK1B
CLECL1
MEP1B

τb1,j (95% CI)
2.981 ( 1.722, 4.235)
-2.933 (-4.226,-1.493)
2.927 ( 1.712, 4.150)
2.890 ( 1.543, 4.314)
2.822 ( 1.426, 4.122)
2.812 ( 1.374, 4.073)
2.807 ( 1.408, 4.164)
-2.732 (-3.736,-1.689)
-2.730 (-3.509,-1.826)
-2.679 (-3.596,-1.711)
2.666 ( 1.187, 5.143)
2.635 ( 1.423, 3.771)
2.626 ( 1.388, 3.757)
-2.615 (-3.495,-1.618)
-2.564 (-3.285,-1.667)
2.552 ( 1.526, 3.590)
2.539 ( 1.644, 3.365)
-2.535 (-3.340,-1.737)
-2.516 (-3.375,-1.545)
2.498 ( 1.212, 3.745)
2.464 ( 0.749, 3.758)
2.463 ( 1.443, 3.594)
-2.440 (-3.243,-1.684)
2.421 ( 1.267, 3.596)
2.419 ( 1.211, 3.383)
2.419 ( 1.027, 3.763)
2.418 ( 0.995, 3.391)
2.379 ( 1.244, 3.331)
2.361 ( 1.361, 3.349)
2.359 ( 1.069, 3.745)
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τb0,j (95% CI)
-0.197 (-0.682, 0.221)
0.614 ( 0.082, 1.123)
0.131 (-0.324, 0.510)
-0.161 (-0.636, 0.281)
0.089 (-0.307, 0.508)
-0.193 (-0.587, 0.236)
-0.035 (-0.531, 0.460)
0.814 ( 0.404, 1.231)
0.874 ( 0.561, 1.145)
0.905 ( 0.525, 1.324)
0.337 (-1.066, 0.850)
-0.369 (-0.826, 0.056)
-0.947 (-1.385,-0.466)
0.884 ( 0.548, 1.197)
0.965 ( 0.633, 1.261)
-0.902 (-1.317,-0.497)
-0.832 (-1.182,-0.440)
1.150 ( 0.778, 1.512)
1.056 ( 0.667, 1.411)
0.169 (-0.261, 0.558)
0.001 (-0.443, 0.538)
-0.821 (-1.237,-0.450)
1.139 ( 0.805, 1.464)
0.060 (-0.332, 0.437)
-0.879 (-1.302,-0.374)
-0.041 (-0.566, 0.467)
-0.898 (-1.293,-0.386)
-0.725 (-1.131,-0.262)
-0.786 (-1.159,-0.415)
0.157 (-0.259, 0.550)

expression are associated with longer CRC recurrence-free survival time.
Additionally, SCEL and TGIF1 have the largest negative τb1 = −2.933 associated
with the recurrence-free survival time. TGIF1 was found to be positively correlated
with the proliferation and migration of the CRC cancer cells (Wang et al., 2017) while
the knockdown of SCEL was discovered to promote the migration and metastasis of
CRC (Chou et al., 2016). Based on our analysis results, the negative correlation
between SCEL and TGIF1 expression is associated with longer CRC recurrence-free
survival time.

(a) Profile plots between C18orf12 and MEP1B with τb1 = 2.98

(b) Profile plots between SCEL and TGIF1 with τb1 = −2.93

Figure 3.2. Profile plots for the top two gene pairs with the largest |τb1 | associated
with recurrence-free survival time. (a) presents the profile plots between C18orf12
and MEP1B with τb1 = 2.98; (b) presents the profile plots between SCEL and TGIF1
with τb1 = −2.93. Gene expression levels were standardized to have mean 0 and
variance 1 in both plots.
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In Figure 3.3, the top 19 gene pairs (33 genes) with |τb1,j | (≥ 2.5) are shown as
nodes in this network plot. The thickness of the edges represents the values of |τb1,j |.
Genes linked with dash lines in the network represent negative τb1,j values while edges
with solid lines denote positive τb1,j values. The genes linked together can be seen
as a co-expression gene group where the correlations among genes are closely related
to the recurrence-free survival time. For example, MEP1B, C18orf12, METTL6 and
POLR3A are a such group where MEP1B acts as a “hub” that shows dynamic gene
co-expression associated with colorectal cancer recurrence-free survival time with all
other genes in this group.

3.6

Discussion

In the past two decades, several useful statistical tools (Li, 2002; Lai et al., 2004; Ho
et al., 2011; Gunderson and Ho, 2014; Kinzy et al., 2019) have been developed for
identifying dynamic co-expression in single combination of genes. When considering
a small number of genes, one can perform the analysis for all possible gene combinations one after another. This search strategy is known as the exhaustive search (ES)
algorithm. In a typical genome-wide dataset, the ES algorithm can quickly become
computational intensive as the number of considered genes increases. This chapter
aims to develop new DC models to supplement the statistical tools for high dimensional search space with highly sparse DC signals where the existing ES algorithm is
intractable.
In this chapter, we propose the SPSL model and the C-SPSL model with the implementation of variable selection technique in a Bayesian framework. The proposed
approaches possess several advantages. First, in a sparse data matrix, the proposed
methods can shrink gene pairs with weak or zero DC signals via variable selection
procedure so that the algorithms can reduce the false discovery error rate. Second,
the proposed method has the capacity to incorporate the dependence structure be-
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Figure 3.3. Network plot for gene pairs with |τb1,j | ≥ 2.5 (33 genes with 19 pairs).
Nodes represent genes and the thickness of the link edges indicate the values of |τb1,j |.
Dotted lines indicate gene pairs with negative τb1,j while solid lines denote positive
τb1,j values.
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tween the parameters of interest τ1 to improve the performance of estimates. By
setting a global prior for the selection variable as presented in Equation (3.5), the
C-SPSL model achieves lower FDR and FNR comparing to SPSL, in the situation
with highly sparse signals and a large search space as seen in our simulation scenario
II. Third, the proposed methods do not assume the modulating factors to be normally distributed gene expression data, providing great flexibility in the discovery
of modulatory mechanisms in the biological systems. Fourth, the shrinkage nature
allows the proposed method to focus on the small subset of gene-pair combinations
that exhibit DC signals so that they can alleviate the computational intensiveness
during the estimation process.
To control the extent of parameter shrinkage and dispersion, the values of the
hyperparameters in the prior distributions can be modified accordingly. For example,
as demonstrated in Figure 3.1, a larger value of v0 can be set for less shrinkage in the
situation with less sparsity.
In addition, we assumed Fisher’s Z-transformation of the gene interactions to be
linear with the cancer recurrence risk as presented in Equation (3.2). In practice,
the association patterns could be more flexible. Using various transformations and
non-linear associations can be easily adapted to the proposed modeling framework.
With the increasing availability of data generated by next-generation RNA sequencing (RNA-seq), it is of practical significance to discuss how to apply our proposed models to RNA-Seq read count data. While the models were designed for the
gene normally distributed expression data, our proposed models are still applicable
to count data after proper pre-processing. One can use the log normalized RNA-Seq
read count data through adaptive technology such as Voom (Law et al., 2014) to ensure the transformed data correspond to a normal distribution. Moreover, developing
a negative binomial model for systematically identifying DC is also a feasible option
for modeling RNA-Seq read count data for future research.
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Chapter 4
Subject-specific Model for Identifying Dynamic
Gene Co-expression as Biomarkers for
Classification using Bayesian Variable
Selection for Single-Cell Count Data
4.1

Introduction

Advancements of next-generation sequencing technologies have enabled the generation of genetic data in individual cells and provided valuable insights into functions
and behaviors of cells at various stages and cell types. In recent years, single-cell studies have been increasingly carried out to unveil the potential discoveries in genetic
regulation mechanisms and interactions (Hwang et al., 2018). In a complex biological
system, however, gene interaction in a genetic circuit are often highly dynamic and
tightly coordinated by other modulating factors (Green et al., 2009; Qiu et al., 2011;
Sambandan et al., 2006). In response to various external signals or changes in cellular states, interactions between genes can be activated or switched off. The dynamic
change between gene interactions under various biological conditions is named dynamic gene coexpression (DC). Studying the dynamic changes using single-cell RNA
sequencing (scRNA-seq) data can uncover the complex underlying genetic regulatory
mechanisms in a high-resolution perspective.
Statistical methods for the identification of DC have been established and validated in past studies (Li, 2002; Li et al., 2004; Lai et al., 2004; Ho et al., 2011;
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Gunderson and Ho, 2014; Yu, 2018; Kinzy et al., 2019). Li (2002) proposed a direct approach named liquid association to measure the DC between a pair of genes
conditioning on a third gene using a three-product moment statistic. This method formulated the foundation of DC estimation and provided a new perspective on studying
gene interactions and the underlying genetic regulatory mechanisms. Ho et al. (2011)
extended the work and proposed a conditional normal model to consider interdependencies of mean, variance as well as the correlation in a gene triplet. To accelerate
the process of identification of DC in high dimensional datasets, Gunderson and Ho
(2014) developed a useful screening approach to reduce the number of gene triplets
under consideration hence significantly reducing the computational time.
These methods mainly focused on continuous transcriptional data and assumed
the gene expression levels to be Gaussian. However, scRNA-seq read count data are
usually non-negative integers with a proportion of raw counts to be zero (Ma et al.,
2020; Yang and Ho, 2021). The implementation of the aforementioned approaches
require transforming count data into continuous measures and hence is unable to
account for zero-inflation and over-dispersion in scRNA-seq data. To handle the
over-dispersion and count-based marginal distributions for scRNA-seq data, Ma et al.
(2020, 2022) established frameworks of using Poisson-Gamma mixture models to generate negative binomial distributions for count data and implementing copula methods to estimate DC in gene pairs. Yang and Ho (2021) proposed zero-inflated negative
binomial dynamic correlation model (ZENCO) to incorporation zero-inflation in DC
estimation with a Bernoulli-negative-binomial mixture model. These work provided
ground-breaking opportunities to identify dynamic patterns of gene interactions for
scRNA-seq count data across all cells.
In a typical scRNA-seq dataset, gene expression profiles are usually collected from
multiple subjects such as different patients or tissues. The multi-subject scRNAseq data are often characterized by individual difference and sparsity in gene co-
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expressions (He et al., 2021). Considering subject-specific characterization can increase the accuracy of identifying DC gene pairs and provide great opportunity in
using individual DC gene pairs as biomarkers in studying clinical outcomes. Motivated by this, we propose a mixed-effect model for scRNA-seq DC identification
while incorporating subject-specific random effects and zero-inflation in scRNA-seq
datasets.
Since the DC signal is often sparse among gene pairs, we also consider a Bayesian
spike-and-slab variable selection approach in the mixed-effect framework to identify
DC gene-pairs. The proposed mixed-effect spike-and-slab (ME-SPSL) model can focus on subsets of individuals with significant random effects while shrinking others
to zero (George and McCulloch, 1993). Furthermore, we set out to use individual
DC gene-pairs as biomarkers to classify subjects into different subgroups. In terms
of the melanoma datasets (Jerby-Arnon et al., 2018) used in the experimental analysis in this article, the cells sampled from different patients were characterized by
immunotheropy-resistant and non-resistant subgroups. The proposed methods can
offer new insights into gene-pair biomarkers in clinical studies.
This article is organized in the following structure. Section 4.2 elaborates the proposed mixed-effect models for DC estimation using spike-and-slab variable selection
method (ME-SPSL) and provides the description of the dataset used in this paper.
Section 4.3 presents three simulation studies to compare the performance of the proposed model with the competing methods in identifying DC gene pairs and using the
DC measurement as the biomarkers for subject classification. Section 4.4 describes
an experimental data analysis using the proposed ME-SPSL model in a melanoma
dataset for DC estimation and immunotheropy-resistant sample classification. At
the end, Section 4.5 concludes the article and discusses the future work in the related
area.
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4.2
4.2.1

Materials and Methods
Datasets and Databases

The dataset used in this paper were obtained from an immunotherapy study for
melanoma and can be accessed from Gene Expression Omnibus (GEO) with accession number GSE115978. This study aimed to identify cells with scRNA-seq profiles that were associated with immune checkpoint inhibitor (ICI) resistance. The
dataset contains 7,186 cells from 33 melanoma tumors, among which 15 samples were
ICI-resistant. The scRNA-seq data were collected using 10x Genomics Chromium
platform (Jerby-Arnon et al., 2018) and the gene profiles were mapped to the UCSC
hg19 human transcriptome using STAR (Dobin et al., 2013). The cells were identified based on the expression levels and inferred copy-number variation (CNV) profiles
(Jerby-Arnon et al., 2018). After cells identification and gene profiles mapping, 10,483
genes and 6,173 melanoma cells were available in the experimental dataset.

4.2.2

Methods

Suppose scRNA-seq read count data are collected from K subjects and nk cells per
subject. Let Yijk represent the scRNA-seq count data for i-th gene in j-th cell from
k-th subject, where i = 1, 2, j = 1, ..., nk , and k = 1, ..., K. As suggested by Yang
and Ho (2021); Ma et al. (2020), a negative binomial mixture can be used to model
count data while account for zero-inflation. Considering the subject-specific random
effects, the negative binomial mixture is formulated as follows:
Yijk | γijk , µik , ϕi ∼ γijk I0 + (1 − γijk )N B(µik , ϕi ),

(4.1)

where I0 is a point mass function at 0; and γijk ∼ Bernoulli(pik ) is a binary dropout
indicator with cell-invariant dropout probability of pik . As γijk = 1, the expression
level of gene Yijk = 0 and vice versa. The negative binomial component is assumed
to have mean (µik ) for all cells and measurement of dispersion (ϕi ) for all cells and all
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subjects. To account for the subject-specific random effects on the mean, we assume
µik ∼ N (µ, σµ2 ), where µ is the fixed effect on the mean of the negative binomial
distribution and σµ2 is the variance. We set µ ∼ N (0, 103 ) and σµ2 ∼ IG(1, 0.001).
The dropout probability pik can be modeled as a logistic function of the subjectspecific mean (pik =

eb0 +b1 µik
)
1+eb0 +b1 µik

and estimated from the real dataset. Based on the

melanoma dataset as described in Section 4.2.1, the parameters b0 and b1 can be
estimated using a logistic regression.
Our goal of this research is to model the dynamic gene co-expression between Y1jk
and Y2jk modulated by xjk . Following Ma et al. (2020), we model the correlation between Y1jk and Y2jk by introducing latent bivariate normal variables and constructing
the negative binomial distribution in Equation (4.1) using a poisson-gamma mixture.
Let zjk = (z1jk , z2jk )T be latent bivariate normal variables such that
  



0  1 ρjk 
  
 ,
zjk ∼ N2 
  , 

0
ρjk 1

(4.2)

where ρjk is the correlation coefficient between Y1jk and Y2jk in j-th cell and kth subject; and zijk ∼ N (0, 1), marginally. Let Yijk | uijk , µik ∼ P oisson(µik uijk )
and uijk | ϕi ∼ Gamma(1/ϕi , 1/ϕi ). By integrating out uijk from the posterior
distribution of Yijk , uijk | µik , ϕi , the negative binomial distribution can be derived:
Yijk | µik , ϕi ∼ N B(µik , ϕi ) with E(Yijk ) = µik and V ar(Yijk ) = µik (1 + ϕi µik ).
Furthermore, let F (·) be the cumulative distribution function of gamma distribution
with same shape and scale parameter 1/ϕi . Therefore, the distribution of Yijk can be
written as:
Yijk | γijk , µik , ϕi , zijk ∼ γijk I0 + (1 − γik )P oisson(Fα−1
[Φ(zijk )]µik ).
i

(4.3)

When γijk = 0, Yijk follows a negative binomial distribution.
We define the dynamic gene co-expression between Y1jk and Y2jk changing with
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the modulating factor xjk as follows:
1 + ρjk
log
1 − ρjk
where log



1+(·)
1−(·)



!

= τ0k + τ1k × xjk ,

(4.4)

is the Fisher’s Z-transformation to ensure that ρjk falls within (-1,1)

and hence ρjk =

(τ

+τ

×x

)

e 0k 1k jk −1
;
(τ +τ ×x )
e 0k 1k jk +1

τ0k and τ1k represent the measurement of baseline

co-expression (BC) and the dynamic gene co-expression (DC). By assuming τ0k ∼
N (τ0 , σ02 ) and τ1k ∼ N (τ1 , σ12 ), where σ02 > 0 and σ12 > 0 are variances, the subjectspecific random effect on the dynamic gene co-expression can be modeled. Here τ0
and τ1 are fixed effect of BC and DC across subjects and τ1 is the parameter of
interest.
Considering the subject-specific random effects on DC can be sparse, we propose
a spike-and-slab random effect model (ME-SPSL) to apply variable selection to DC
random effects. As suggested by George and McCulloch (1993); Ishwaran et al. (2005),
we implement a spike-and-slab prior on τ1k and formulate the proposed structure as
follows,
  

1
0 
  
zjk | τ0k , τ1k , xjk ∼ N2 
  ,  (τ0k +τ1k ×xjk )
e
−1
0
(τ0k +τ1k ×xjk )
e

+1

τ0k | τ0 , σ02 ∼ N (τ0 , σ02 )

(τ

+τ

×x

)



e 0k 1k jk −1

(τ +τ ×x )
e 0k 1k jk +1 

1



(4.5)

τ1k | wk ∼ wk N (τ1 , I ) + (1 − wk )Iτ1
wk | sk ∼ Bernoulli(sk )
sk ∼ U (0, 1).
In this framework, τ1k ’s prior is assumed to be a Gaussian mixture. The “slab" part
is a normal distribution N (τ1 , I ) with a mean of fixed effect τ1 and hypervariance
I . The “spike" part is a point mass function centered at τ1 to ensure the expectation
of τ1k ’s prior distribution is τ1 . The shrinkage indicator wk is a binary variable with
1 indicating normal estimation and 0 referring to τ1k ’s shrinking towards τ1 . In the
proposed framework, we set non-informative conjugate priors to τ0 , τ1 and I to
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ensure that the parameters can be well estimated: τ0 ∼ N (0, 103 ), τ1 ∼ N (0, 103 )
and I ∼ IG(0.01, 0.01).
4.2.3

Estimation

Let θ represent the vector of all the parameters and latent variables including τ0k ’s,
τ1k ’s, τ0 , τ1 , σ02 , µ1k ’s, µ2k ’s, µ, σµ2 , ϕ1 , ϕ2 , γ1k ’s, γ2k ’s, z1jk ’s, z2jk ’s, I , wk ’s and sk ’s.
The likelihood function of θ is given by
L(θ | Y, x) =

nk
K Y
Y

f (Y1jk , Y2jk | xjk , θ),

k=1 j=1

where f (·) is the joint density function of (Y1jk , Y2jk )T . The posterior joint distribution
for θ with prior joint distribution π(θ) can be written as
π(θ | Y, z) ∝

nk
K Y
Y

f (Y1jk , Y2jk | xjk , θ) × π(θ).

k=1 j=1

4.3

Simulation

To assess the performance of our proposed ME-SPSL model, three simulation studies
were conducted to compare the proposed model with two other competing approaches,
zero-inflated negative binomial dynamic correlation model Yang and Ho (2021) with
random effects (ZENCO-ME) and ZENCO without random effects.

4.3.1

Scenario I

In the first simulation scenario, we evaluated the performance of our proposed MESPSL model and the competing methods in identifying DC from a single pair of zeroinflated scRNA-seq count data. We simulated K = 30 subjects, each with nk = 50
cells. The simulated data contain a single pair of count data Yjk = (Y1jk , Y2jk )T and
a continuous modulating factor xjk in j-th cell from k-th subject, where j = 1, ..., nk
and k = 1, ..., K. The data were generated in the following procedure.
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First, we sampled subject-specific measurements of DC. For k-th subject, τ0k was
2
sampled from N (τ0 , σ02 ) and τ1k was sampled from N (τ1 , σ1k
), where τ1 is the fixed

effect on DC across all subjects. The variance of random effects σ12 was set equal to
10−4 and 10−2 . We used the same simulation procedure to simulate nk = 50 cells for
k
from N (0, 1) was generated as the modulating factor.
each subject. A set of {xjk }nj=1

Next, the correlation coefficient was calculated, ρjk =
T

(τ

+τ

tent variables zjk = (z1jk , z2jk ) were generated such that zjk ∼
The count data Yjk were simulated using zjk

x

)

e 0k 1k jk −1
.
(τ +τ x )
e 0k 1k jk+1

Then the la



0 
 
N2 
 ,


1

ρjk  



ρjk 1
0
as discussed in Equation (4.3). The

dropout indicators γ1jk and γ2jk were generated from Bernoulli distributions, where
the dropout probabilities p1k and p2k were estimated from the real dataset as discussed
in Section 4.2.2.
In this scenario, we evaluated the performance of the proposed model to identify
the measurement of the fixed effect of dynamic gene co-expression (τ1 ) while considering the subject-specific random effects in a single pair of genes. Power analysis was
used to compare the model with two other competing approaches: ZENCO-ME and
ZENCO. For testing the existence of dynamic co-expression changes, our hypotheses
were set up as:
H0 : τ1 = 0 versus H1 : τ1 ̸= 0.
We set b0 = −0.698, b1 = −0.076 which were estimated using the real dataset.
The other parameters were set as µ1 = µ2 = 30, σµ = 1, ϕ1 = ϕ2 = 2, σ02 = 10−4 .
The true value of τ1 was set ranging from 0 to 0.5 while τ0 was set equal to 0. The
statistical power can be calculated as the percentage of the posterior 95% credible
intervals of τ1 not including zero in the 200 simulations.
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4.3.2

Scenario II

An additional simulation was conducted to evaluate the performance of the proposed
model and competing methods when the variances of τ1k are random. The variance
of DC for the k-th subject σ12 was chosen at randomly from the set of (10−4 , 10−2 , 1),
resulting in some τ1k ’s widely spread and some highly concentrating around τ1 . While
maintaining all parameters the same as in Section 4.3.1, we implemented power analysis to evaluate the performance of identifying τ1 .

4.3.3

Scenario III

In this scenario, we evaluated the performance of our proposed ME-SPSL model
compared to ZENCO-ME in subjects classification using subject-specific DC as the
biomarkers. Following the data generation procedure in Section 4.3.1, we simu(l)

lated 4 pairs of count data {Yjk }3l=1 based on the same xjk and a set of τ1 =
(1)

(2)

(3)

(4)

(τ1 , τ1 , τ1 , τ1 ) = (0, 0.2, 0.3, 0.5) in j-th cell from k-th subject. For l-th pair,
(l)

(l)

(l)

2
2
was
) with corresponding τ1 , l = 1, 2, 3, 4, while σ1k
we generated τ1k ∼ N (τ1 , σ1k

randomly chosen from the set of (10−4 , 10−2 , 1) as described in Section 4.3.1. Other
parameters including the number of cells and subjects were all set the same as in
Section 4.3.1. Next, the binary class for k-th subject was generated in terms of a
Bernoulli distribution with probability p∗k , which was calculated based on the logistic
function p∗k =

eβ0 +βτ1k
.
1+eβ0 +βτ1k

The parameters β were set equal to (1, 1, 1, -1) with the

intercept β0 being equal to 0 so that the number of classes were not imbalanced.
In ME-SPSL and ZENCO-ME models, τ1k were estimated first from all combinations of Yjk and then used as biomarkers to classify subjects into two groups using
logistic regression. Pairs of genes were selected based on the significance of τ1 . Receiver operating characteristics (ROC) curve and area under curve (AUC) score were
used to evaluate the performance in classification.
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Figure 4.1. Power curves for τ1 for ME-SPSL, ZENCO-ME, and ZENCO model
based on 200 simulations and fixed σ12 .
4.3.4

Results

All methods were implemented through automated Markov Chain Monte Carlo (MCMC)
compiler JAGS (Plummer et al., 2003) with 10,000 iterations, 2,000 burn-ins, and 3
chains. The results of Gelman-Rubin convergence diagnostics (Gelman et al., 1992)
are provided in Table 4.1. Gelman-Rubin convergence diagnostics statistics were all
less than 1.2, which indicates good convergence (Brooks and Gelman, 1998). The
calculation was implemented on computing clusters nodes each with the Intel(R)
Xeon(R) CPU @ 2.40GHz processor.
Figure 4.1 presents the power curves for scenario I (Section 4.3.1) with fixed
σ12 . The ME-SPSL is more powerful than ZENCO-ME when σ12 is small. As shown
in Figure 4.2, ZENCO fails to control the type I error in all cases. Our proposed
ME-SPSL can successfully maintain type I error and achieve greater power than
ZENCO-ME.
Figure 4.2 presents the power plots for the proposed ME-SPSL model and the
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Table 4.1. Gelman-Rubin convergence diagnostics results for a randomly picked
sample among 200 simulations. Point estimates of the potential scale reduction factor
(Point est.) and their upper confidence limits (Upper C.I.) are provided.
σ02
τ0
τ0,1
τ0,2
τ0,3
τ0,4
τ0,5
τ0,6
τ0,7
τ0,8
τ0,9
τ0,10
τ0,11
τ0,12
τ0,13
τ0,14
τ0,15
τ0,16
τ0,17
τ0,18
τ0,19
τ0,20
τ0,21
τ0,22
τ0,23
τ0,24
τ0,25
τ0,26
τ0,27
τ0,28
τ0,29
τ0,30

Point est.
1.01
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00

Upper C.I.
1.01
1.00
1.00
1.00
1.01
1.00
1.01
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.01
1.00
1.00
1.01
1.00
1.01
1.01
1.01
1.00

σ12
τ1
τ1,1
τ1,2
τ1,3
τ1,4
τ1,5
τ1,6
τ1,7
τ1,8
τ1,9
τ1,10
τ1,11
τ1,12
τ1,13
τ1,14
τ1,15
τ1,16
τ1,17
τ1,18
τ1,19
τ1,20
τ1,21
τ1,22
τ1,23
τ1,24
τ1,25
τ1,26
τ1,27
τ1,28
τ1,29
τ1,30
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Point est. Upper C.I.
1.00
1.01
1.00
1.00
1.00
1.00
1.00
1.01
1.00
1.01
1.00
1.00
1.00
1.00
1.00
1.00
1.01
1.03
1.00
1.00
1.00
1.00
1.01
1.02
1.00
1.01
1.00
1.01
1.01
1.02
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.01
1.00
1.00
1.01
1.01
1.00
1.01
1.00
1.01
1.00
1.00
1.00
1.01
1.00
1.00
1.00
1.02
1.00
1.01
1.01
1.01
1.00
1.01

Figure 4.2. Power curves for τ1 for ME-SPSL, ZENCO-ME and ZENCO model
based on 200 simulations and random σ12 .
competing methods: ZENCO-ME and ZENCO models over 200 simulations for scenario II as described in Section 4.3.2. As shown in Figure 4.2, ME-SPSL outperforms
ZENCO-ME while ZENCO fails to control the type I error. Since ZENCO estimates
τ1 without considering the subject-specific random effects, it tends to overestimate
τ1 when the values of τ1 are near 0. The implementation of variable selection can
effectively identify the fixed effect τ1 while shrinking the small random effects to 0 to
increase the power of identification of τ1 .
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Table 4.2 lists the coverage probability of the 95% credible interval (CP), the
length of the 95% credible interval (CI length), mean square errors (MSE) and mean
bias errors (MBE). The MSE and MBE evaluate the deviations between the posterior
mean of τ1 from the MCMC samples and the true values. The MSE and MBE are
calculated as M SE =

1
(τ̂
ns 1

− τ1 )2 and M BE =

1
(τ̂
ns 1

− τ1 ), where ns is the number

of simulations; τ̂1 is the posterior mean of τ1 estimates from the MCMC samples. As
presented in Table 4.2, CPs of ME-SPSL and ZENCO-ME are all around 0.95 and
ME-SPSL has narrower credible intervals than ZENCO-ME.
Table 4.2. Coverage probability (CP) and the length of 95% credible interval (CI
length), mean square errors (MSE), mean bias errors (MBE) are used as metrics
to evaluate the performance of estimating τ1 ranging from 0 to 0.5 for ME-SPSL,
ZENCO-ME and ZENCO models based on 200 simulations.
τ1
Model
ME-SPSL

ZENCO-ME

ZENCO

Metric
CP
CI length
MSE
MBE
CP
CI length
MSE
MBE
CP
CI length
MSE
MBE

0
0.93
0.38
0.01
0.00
0.90
0.49
0.02
0.00
0.72
0.25
0.01
0.00

0.05
0.95
0.38
0.01
0.00
0.93
0.48
0.02
0.01
0.77
0.25
0.01
0.00

0.1
0.97
0.38
0.01
0.00
0.98
0.48
0.01
0.01
0.80
0.25
0.01
0.00

0.15
0.92
0.38
0.01
-0.01
0.94
0.49
0.02
-0.01
0.76
0.25
0.01
-0.02

0.2 0.25
0.3
0.4
0.5
0.96 0.95 0.94 0.97 0.97
0.38 0.38 0.38 0.38 0.38
0.01 0.01 0.01 0.01 0.01
-0.01 -0.00 -0.01 -0.01 0.00
0.95 0.96 0.94 0.97 0.94
0.48 0.49 0.49 0.48 0.49
0.01 0.02 0.01 0.01 0.02
-0.01 -0.01 -0.01 -0.01 0.01
0.78 0.78 0.76 0.81 0.78
0.25 0.25 0.25 0.25 0.25
0.01 0.01 0.01 0.01 0.01
-0.02 -0.02 -0.03 -0.03 -0.03

Figure 4.3 presents the results of subgroup classification for scenario III as described in Section 4.3.3, which compares the classification results between ME-SPSL
and ZENCO-ME using subject-specific DC estimates as the biomarkers. Samples
were randomly separated into a traning set (20 samples) and a validation set (10
samples). The average ROC curves for validation sets over the 200 simulations are
presented in bold. The ME-SPSL outperforms the ZENCO-ME since the average
AUC score of both the training sets and the validation sets of ME-SPSL (0.81/0.72)
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Figure 4.3. ROC curves for subgroup classification. Black lines represent the average ROC curve for ME-SPSL method and red dashed lines represent the ZENCO-ME
method.
is higher than ZENCO-ME (0.78/0.70).

4.4

Experimental Data Analysis

In this section, we demonstrated the implementation of our proposed ME-SPSL
model and DC-based classification strategy with an experimental analysis using the
melanoma dataset as discussed in Section 4.2.1. This dataset contains 10,483 genes,
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6,173 melanoma cells from 32 different melanoma samples. We considered genes
in the KEGG melanoma pathway with Entry ID of hsa05218 (Kanehisa and Goto,
2000). After screening out genes with more than 80% zero counts, 32 genes remained,
resulting in 496 gene-pair combinations.
In this study, our goal was to identify gene pairs with significant non-zero τ1 associated with the overall expression (OE) score of the gene sets and use the subjectspecific τ1k ’s, where k refers to the k-th melanoma sample (k = 1, ..., 32), in the
corresponding significant gene pairs as the biomarkers to classify the melanoma samples into ICI-resistant group and non-resistant group. The cell-based OE score was
used as the modulating factor x, which is the measurement for the average expression
of genes across all cells and the subjects in a single-cell genomic dataset (Jerby-Arnon
et al., 2018). After standardizing x with the mean and the standard deviation, the
proposed ME-SPSL was implemented on the pairwise gene combinations to estimate
τ1 and τ1k ’s.
We implemented the ME-SPSL model using MCMC compiler JAGS with 20,000
iterations, 10,000 burn-ins and 3 chains. As suggested by Wang and Dunson (2010),
the Bayesian multiple hypothesis testing procedure was applied to control the false
discovery rate (FDR) of identifying DC gene pairs. For the j-th gene pair, the local
(j)

(j)

(j)

hypothesis was defined as, H0 : |τ1 | < ϵ vs. Ha(j) : |τ1 | ≥ ϵ. The threshold ϵ was
determined based on the distributions of τb1 (the posterior mean of τ1 ). As shown in
Figure 4.4 which presents the comparison between the distributions of τb1 that the
95% credible intervals of τ1 (95% CIs) from the MCMC posterior samples include
or exclude zero, ϵ = 0.16 is the minimum τb1 that the 95% CIs exclude zero. By
controlling the FDR at 0.05 level, 140 gene pairs were identified as significant.
Table 4.3 lists the top 30 gene pairs with the largest |τb1 | within the 140 significant
gene pairs. Gene IGF1R is included in all the top three pairs. IGF1R is a well-known
growth factor I receptor that regulates cells’ growth and apoptotic events and was
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Figure 4.4. Density plots of the posterior mean (τb1 ) for the groups including or
excluding zero from the 95% credible intervals (95% CI) of τb1 . The value of ϵ denotes
the minimum of |τb1 | in the significant group that 95% CI excludes 0.
found to play an important role in the treatment of melanoma (Karasic et al., 2010).
We then use the subject-specific τ1k ’s in the significant gene-pairs as the biomarkers (DC-based strategy) and in logistic regression to classify the melanoma samples
into ICI-resistant and non-resistant groups. An expression-based strategy was considered as the benchmark method, which considers the subject-specific mean expression
of genes as the biomarkers, to demonstrate the performance of DC-based strategy in
classification. We also implemented principle component analysis to reduce the dimension of the biomarkers to avoid singularity issues in logistic regression procedure.
The optimal number of principal components was determined as 6 for both strategies
based on wold-style cross validation (Owen and Perry, 2009). Ten-fold Repeated random sub-sampling validation (Monte Carlo cross-validation) (Dubitzky et al., 2007)
was used to split the dataset into ten training (20 samples) and validation sets (12
samples). The predictive accuracy was assessed using average ROC curve and AUC
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Table 4.3. The top 30 significant gene pairs with the largest posterior mean |τb1 |
associated with OE score. The 95% posterior credible intervals of |τb1 | (95% CI) are
provided.
Rank
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

Gene I
IGF1R
AKT2
PIK3CD
MET
AKT3
MAPK1
AKT3
AKT2
RAF1
PIK3R1
AKT2
IGF1R
CDK4
PIK3CD
AKT2
PIK3CD
E2F3
AKT2
IGF1R
RAF1
BAX
CDK4
CDK4
PIK3R1
FGFR1
PIK3R1
AKT2
MET
IGF1
MET

Gene II
BAK1
IGF1R
IGF1R
CDH1
ARAF
DDB2
BAK1
FGFR1
CDK4
GADD45B
IGF1
DDB2
BAK1
CDK4
MITF
AKT3
MITF
GADD45B
MDM2
E2F3
RAF1
DDB2
E2F3
POLK
GADD45B
MITF
RB1
E2F3
MET
GADD45B
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τb1
1. 027
-0. 942
-0. 882
-0. 828
0. 782
0. 732
0. 699
-0. 694
0. 694
0. 691
0. 679
0. 678
0. 675
-0. 675
-0. 670
-0. 664
0. 654
0. 650
-0. 647
0. 641
0. 640
0. 635
0. 633
0. 632
0. 631
-0. 624
0. 622
0. 612
0. 609
0..601

95% CI
( 0.721, 1.325)
(-1.528,-0.319)
(-1.202,-0.456)
(-1.147,-0.551)
( 0.381, 1.125)
( 0.300, 1.168)
( 0.365, 1.031)
(-1.030,-0.420)
( 0.460, 0.912)
( 0.389, 1.032)
( 0.252, 0.969)
( 0.128, 1.137)
( 0.406, 0.912)
(-0.887,-0.428)
(-1.067,-0.333)
(-0.972,-0.314)
( 0.180, 1.161)
( 0.189, 1.016)
(-1.135,-0.241)
( 0.289, 1.094)
( 0.337, 1.016)
( 0.314, 0.961)
( 0.373, 0.968)
( 0.282, 0.988)
( 0.288, 1.016)
(-0.909,-0.340)
( 0.319, 0.918)
( 0.206, 0.963)
( 0.008, 1.078)
( 0.266, 0.894)

Figure 4.5. Average ROC curves for validation sets of ICI-resistant classification.
The average AUC score of DC-based method (black solid line) is 0.65 and the average
AUC score of the expression-based method (red dashed line) is 0.61.
score through the multiple validation sets.
Figure 4.5 presents the average ROC curves for the ten validation sets over the 10fold Monte Carlo cross-validation. The average AUC scores of the training/validation
sets of the DC-based strategy are 0.81 and 0.65 and that of the expression-based strategy are 0.80 and 0.61. The DC-based strategy provides a preferable tool for clinical
outcome prediction and classification compared to the expression-based strategy.
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4.5

Discussion

In this paper, we proposed a mixed-effect model to study the subject-specific DCs
for zero-inflated and over-dispersed scRNA-seq count data to account for both the
random effect of each subject and the fixed effect across all subjects on DC. Considering the sparsity of subject-specific DC signals, we included a spike-and-slab method
as the variable selection technique in the mixed-effect model to exploit the sparsity
to achieve better performance. Furthermore, we proposed to use subject-specific DC
gene pairs as the biomarkers in subgroup classification. In the proposed DC-based
classification strategy, gene-pair biomarkers are identified first in terms of significant
fixed-effect of DC. The subject-specific DCs are then estimated and used as the inputs
of the logistic regression to implement subgroup classification.
The advantages of the proposed method in studying DC in scRNA-seq datasets
are multifold. First, compared with the existing method, the proposed method can
estimate both the random effects and the fixed effects while account for the zeroinflation and over-dispersion in count data. The proposed method can avoid overestimating the DC when random effects exist and hence perfectly control the type I error.
Second, the ME-SPSL method can exploit the sparsity of DC signals to boost the statistical power in identifying DC, especially when subject-specific random effects have
different variances. Third, the proposed subject-specific model provides an exciting
opportunity to implement DC-based classification strategy to use DC gene pairs as
biomarkers in clinical subgroups classification. Compared to the expression-based
strategy which directly uses the subject-specific mean expression of each gene as the
biomarkers in classification, the DC-based strategy can achieve better performance.
Finally, The DC-based classification strategy provides an innovative perspective in
disease-related biomarkers identification and clinical outcomes predictive studies.
We applied our proposed method to a melanoma scRNA-seq dataset. The overall
expression for each cell in the entire dataset was used as the modulating factor.
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The OE score is continuous and normally distributed. In practice, our proposed
method can be used to model DC associated with data from other distributions
including count data. In the experimental analysis, an exhaustive search strategy was
used to scan over all gene-pair combinations to estimate DC and required screening
procedure to reduce the computational intensiveness. Furthermore, we used the DC
gene pairs as the biomarkers to classify the melanoma samples into ICI-resistant and
non-resistant groups. Through Monte-Carlo cross-validation, we showed that the DCbased strategy outperformed expression-based strategy in subgroup classification.
In this paper, we focused on identifying DC in a single gene pair. A possible future
work is to incorporate the dependence structure among DCs of different gene pairs
to extend the proposed model to higher dimensions. In addition, our proposed model
suggests a negative binomial distribution to model the count data. The implementation of copula methods can incorporate more feasible distributions in DC estimation.
Moreover, in subgroup classification, considering other classification methods including machine learning classification techniques, deep learning models is a feasible area
of future work.
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Appendix A
Likelihood and Posterior Distributions for
SPSL and C-SPSL
In this section, we provide the likelihood function and the full conditional distributions
of the parameters involved in the parameter estimation process of the proposed spikeand-slab (SPSL) model and the correlated spike-and-slab (C-SPSL) model as described in Section 3.3. The conditional distribution of the response variable Yi,j |zi , τ0,j , τ1,j
given the covariate zi and parameters of interest τ0,j and τ1,j for i-th observation
(i = 1, ..., n) and j-th gene pair (j = 1, ..., m) is a product distribution of two standard normal distributions with correlation coefficient g −1 (τ0,j + τ1,j zi ) as described in
Section 3.3, where g −1 (·) =

e2(·) −1
e2(·) +1

is the inverse function of Fisher’s Z-transformation.

Based on the independence assumption, the likelihood function is given as follows,
L(τ0 , τ1 |Y , z) =

m
n Y
Y

1

i=1 j=1 π

q

1 − {g −1 (τ0,j + τ1,j zi )}2

"

K0

e

{g −1 (τ0,j +τ1,j zi )}yi,j
1−{g −1 (τ0,j +τ1,j zi )}2

(A.1)
#

|yi,j |
,
1 − {g −1 (τ0,j + τ1,j zi )}2

where K0 (·) is the second class zero-order modified Bessel function.
Since the prior distributions of τ0 are assumed to be independent standard normal
distributions, the full conditional distribution of τ0 |Y , z, τ1 can be derived as follows,
π(τ0 |Y , z, τ1 ) ∝L(τ0 , τ1 |Y , z) × π(τ0 )
∝

n Y
m
Y

1

i=1 j=1

π 1 − {g −1 (τ0,j + τ1,j zi )}2

q

"

K0

#

e

{g −1 (τ0,j +τ1,j zi )}yi,j
1−{g −1 (τ0,j +τ1,j zi )}2

2

τ
|yi,j |
− 0,j
2 .
×
e
1 − {g −1 (τ0,j + τ1,j zi )}2
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(A.2)

To find the full conditional distribution of τ1 , we introduce a latent variable
ϕj = γj · vj2 for j-th pair of genes as an auxiliary variable to simplify the calculation of
the posterior density of τ1 . Based on the independence assumption and the likelihood
function derived above, the full conditional distribution of τ1 |Y , z, τ0 , ϕ is provided
as follows,
π(τ1 |Y , z, τ0 , ϕ) ∝L(τ0 , τ1 |Y , z) × π(τ1 |ϕ)
∝

n Y
m
Y

1

i=1 j=1

π 1 − {g −1 (τ0,j + τ1,j zi )}2

q

"

K0

#

e

{g −1 (τ0,j +τ1,j zi )}yi,j
1−{g −1 (τ0,j +τ1,j zi )}2

(A.3)

τ2

1,j
|yi,j |
− 21 − 2ϕ
j .
×
ϕ
e
j
1 − {g −1 (τ0,j + τ1,j zi )}2

To find the full conditional distribution of ϕ|τ1 , w, we need to derive the conditional distribution of ϕj |wj first. Since γj |wj is a discrete probability measure
concentrated on either 1 or v0 with probabilities P (γj = 1|wj ) = wj and P (γj =
v0 |wj ) = 1 − wj , the conditional distribution of ϕj |γj , wj can also have two measures.
Recall that ϕj is the product of γj and vj2 , which is assumed to be an inverse gamma
distribution with shape and scale parameters α1 and α2 . The conditional distribution
of ϕj |wj , γj = 1 is IG(α1 , α2 ) while the conditional distribution of ϕj |wj , γj = v0 is
an inverse gamma distribution with a smaller scale parameter IG(α1 , v0 α2 ).
Then we marginalize γj to derive the conditional distribution of ϕj |wj ,
π(ϕj |wj ) = π(ϕj |wj , γj = 1) × P (γj = 1|wj ) + π(ϕj |wj , γj = v0 ) × P (γj = v0 |wj )
=

α2α1 −α1 −1 − αϕj2
(v0 α2 )α1 −α1 −1 − v0ϕαj 2
ϕj
e
× wj +
ϕ
e
× (1 − wj ),
Γ(α1 )
Γ(α1 ) j
(A.4)

which follows a mixture of inverse gamma distributions and can be denoted as
wj IG(α1 , α2 ) + (1 − wj )IG(α1 , v0 α2 ). Therefore, the full conditional distribution
of ϕ|τ1 , w can be derived as follows,
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π(τ1 |ϕ) × π(ϕ|w)
π(τ1 |ϕ) × π(ϕ|w)dϕ

π(ϕ|τ1 , w) = R

=

−(α1 + 12 )−1 −
wj ϕj
e

m
Y

(
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1
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2
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(A.5)

wj

where Cj =


wj

τ2
1,j
2

−α1 − 1
2

+α2

τ2
1,j
2

−α1 − 1
2

+α2

α
+(1−wj )v0 1



τ2
1,j
2

−α1 − 1
2

is a constant for ϕj . Therefore,

+v0 α2

for j-th gene pair, ϕj |τ1,j , wj also follows a mixture of inverse gamma distributions
which can be denoted as Cj × IG(α1 + 21 ,

2
τ1,j
2

+ α2 ) + (1 − Cj ) × IG(α1 + 21 ,

2
τ1,j
2

+ v0 α2 ).

As discussed in the Section 3.3, the difference between the SPSL model and the CSPSL model is that the SPSL model assumes independent uniform prior distributions
for w while the C-SPSL model uses a beta-uniform prior structure to incorporate the
dependence structure in the model. Therefore, the full conditional distribution of
w|ϕ in the SPSL model can be derived as follows,
π(ϕ|w) × π(w)
π(ϕ|w) × π(w)dϕ

π(w|ϕ) = R

α

=

m
Y

(

j=1
−

where Dj =

e

−

e

α

2
−α1 −1 − ϕj

Γ(2)Γ(1)
Γ(3)

j=1

=

α1

2
m
ϕ
Y
Γ(α1 ) j

α2
ϕj

e

× wj +

α
α2 1
Γ(α1 )

α
− ϕ2
j

(v0 α2 )α1 −α1 −1 −
ϕj
e
Γ(α1 )

1 −1
ϕ−α
e
j

+

v0 α2
ϕj

× (1 − wj )

Γ(2)Γ(1) (v0 α2 )α1 −α1 −1 −
ϕj
e
Γ(3)
Γ(α1 )

v0 α2
ϕj

(A.6)

)

Γ(3)
Γ(3)
Dj ×
wj + (1 − Dj ) ×
(1 − wj ) ,
Γ(2)Γ(1)
Γ(2)Γ(1)

α2
ϕj
v α
− 0 2
ϕj

is a constant for wj . The conditional distribution of wj |ϕj is

+e

a mixture of beta distribution which can be denoted as Dj ×B(2, 1)+(1−Dj )×B(1, 2).
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In the C-SPSL model, we assume the conditional distribution of wj |c for j-th pair
of genes to be a beta distribution with global hyperparameters c and 1 − c. The full
conditional distribution of w|ϕ in the C-SPSL model is given by,
π(w|ϕ, c) = R

π(ϕ|w) × π(w|c)
π(ϕ|w) × π(w|c)dϕ
(

=

m
Y

α

α
2
α2 1
−α1 −1 − ϕj
ϕ
e
Γ(α1 ) j

α

α

− 2
Γ(1+c)Γ(1−c) α2 1
ϕ−α1 −1 e ϕj
Γ(2)
Γ(α1 ) j

j=1

=

× wj +

(v0 α2 )α1 −α1 −1 −
ϕj
e
Γ(α1 )

m
Y
j=1

(

Ej ×

+

v0 α2
ϕj

)

× (1 − wj ) × wjc−1 (1 − wj )−c

Γ(c)Γ(2−c) (v0 α2 )α1 −α1 −1 −
ϕj
e
Γ(2)
Γ(α1 )

v0 α2
ϕj

Γ(2)
(1+c)−1
w
(1 − wj )(1−c)−1
Γ(1 + c)Γ(1 − c) j
)

Γ(2)
+ (1 − Ej ) ×
wc−1 (1 − wj )(2−c)−1 ,
Γ(c)Γ(2 − c) j
(A.7)
−

where Ej =

Γ(1+c)Γ(1−c)e
−

Γ(1+c)Γ(1−c)e

α2
ϕj

α2
ϕj
v α
− 0 2
ϕj

is a constant for wj . Therefore, the con-

+Γ(c)Γ(2−c)e

ditional distribution of wj |ϕj , c can be denoted as a mixture of beta distributions,
Ej × B(1 + c, 1 − c) + (1 − Ej ) × B(c, 2 − c).
By assuming a uniform distribution to c, the conditional distribution of c|w in
the C-SPSL model can be derived as follows,
π(c|w) ∝π(w|c) × π(c)
∝

m
Y

1
wjc−1 (1 − wj )−c .
j=1 Γ(c)Γ(1 − c)

(A.8)

With the likelihood function and all the conditional distributions for the hyperparameters derived above, we implemented the adaptive Metropolis-Hastings sampling
scheme and obtained the posterior samples of the parameters of interest. More details
are discussed in the next section.
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Appendix B
Adaptive Metropolis-Hastings Sampling
Algorithm
As discussed in Section 3.3, we developed an efficient Markov Chain Monte Carlo
(MCMC) algorithm using the adaptive Metropolis (AM) algorithm (Haario et al.,
2001). Algorithm 1 and 2 provide the procedures of the adaptive MCMC implemented
in SPSL and C-SPSL, respectively. In the AM algorithm, the proposal distribution is
a multivariate normal distribution centered on the current state, and the covariance
matrix is calculated from a fixed number of previous states. Due to the ranges
of support for various parameters, appropriate transformations are considered with
samples from the multivariate proposal distribution. Because of the symmetry of
the normal proposal distributions suggested in the AM algorithm, the acceptancerejection rate is equivalent to the posterior ratios.
As presented in Algorithm 1 and 2, the sampling process is cut into two stages. In
the initial stage, the proposal distributions are independent normal distributions with
the step size λ = 0.05. After the cutting point th , multivariate normal distribution
with covariance matrix calculated from the history states are used as the proposal
distributions. The covariance matrix is multiplied by a different step size Sd = 10 in
this stage to give an acceptance rate close to 20-30%. A small value ξ (e.g. 0.00001)
is added to the diagonal elements of the covariance matrix to avoid singularity in
the variance-covariance structure. We set the history tracing size as h = 200 when
calculating the covariance matrix to reduce the computation cost (h ≤ th ).
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In the adaptation process (when th < i < tN and tN is the total number of
iteration), the proposal distributions are separated into four groups in the SPSL model
and five groups in the C-SPSL model. Within each group, the covariance matrix of
the multivariate normal distribution is calculated. The groups are segregated in terms
of the objects of the parameters. For example, in the SPSL model, the four groups
are τ0 , τ1 , ϕ, and w while in the C-SPSL model, the five groups are τ0 , τ1 , ϕ, w,
′

and c. The dimension of parameters in each group is denoted as d .
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Algorithm 1: The adaptive Metropolis algorithm implemented in SPSL
(0)

(0)

Initialize the parameters θ (0) = (τ0 , τ1 , ϕ(0) , w(0) ), θ ∈ Rd ;
for i=1 to tN do
if i ≤ th then
Derive q ∗ from the proposal distribution Nd (θ (i−1) , λId ) with
transformations in terms of θ (i−1) ;
for j = 1 to d do
Calculate the acceptance-rejection
(
) rate :
(i−1)

A(qj∗ , θj

) = min 1,

π(qj∗ |·)
(i−1)

π(θj

|·)

;
(i−1)

(i−1)

if A(qj∗ , θj ) ≥ U(0, 1) or A(qj∗ , θj ) = 1 then
(i)
θj = qj∗ ;
else
(i)
(i−1)
θj = θj ;
end
end
end
if i > th then
′
′
′
while θ in each group of (τ0 , τ1 , ϕ, w), θ ∈ Rd do
Derive q ∗ from the proposal distribution
′
′
′
Nd′ (θ (i−1) , Sd cov(θ (i−h) , ..., θ (i−1) ) + ξId′ ) with transformations
′
in terms of θ (i−1) ;
′
for j = 1 to d do
Calculate the acceptance-rejection
(
) rate:
′ (i−1)

A(qj∗ , θj

) = min 1,

π(qj∗ |·)
′ (i−1)

π(θj

′ (i−1)

|·)

;
′ (i−1)

if A(qj∗ , θj
) ≥ U(0, 1) or A(qj∗ , θj
′ (i)
θj = qj∗ ;
else
′ (i−1)
′ (i)
;
θj = θj
end
end
end
end
end
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) = 1 then

Algorithm 2: The adaptive Metropolis algorithm implemented in C-SPSL
(0)

(0)

Initialize the parameters θ (0) = (τ0 , τ1 , ϕ(0) , w(0) , c), θ ∈ Rd ;
for i=1 to tN do
if i ≤ th then
Derive q ∗ from the proposal distribution Nd (θ (i−1) , λId ) with
transformations in terms of θ (i−1) ;
for j = 1 to d do
Calculate the acceptance-rejection
(
) rate :
(i−1)

A(qj∗ , θj

) = min 1,

π(qj∗ |·)
(i−1)

π(θj

|·)

;
(i−1)

(i−1)

if A(qj∗ , θj ) ≥ U(0, 1) or A(qj∗ , θj ) = 1 then
(i)
θj = qj∗ ;
else
(i)
(i−1)
θj = θj ;
end
end
end
if i > th then
′
′
′
while θ in each group of (τ0 , τ1 , ϕ, w, c), θ ∈ Rd do
Derive q ∗ from the proposal distribution
′
′
′
Nd′ (θ (i−1) , Sd cov(θ (i−h) , ..., θ (i−1) ) + ξId′ ) with transformations
′
in terms of θ (i−1) ;
′
for j = 1 to d do
Calculate the acceptance-rejection
(
) rate:
′ (i−1)

A(qj∗ , θj

) = min 1,

π(qj∗ |·)
′ (i−1)

π(θj

′ (i−1)

|·)

;
′ (i−1)

if A(qj∗ , θj
) ≥ U(0, 1) or A(qj∗ , θj
′ (i)
θj = qj∗ ;
else
′ (i−1)
′ (i)
;
θj = θj
end
end
end
end
end
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Appendix C
Empirical distributions of τb1 in CRC Dataset
Let τb1 be the posterior mean of τ1 based on all 949, 280 gene pairs after the screening
step as described in the Section 3.5. The empirical density plot of τb1 is presented in
Figure C.1. As observed in Figure C.1, the proportion of |τb1 | being greater than 0.5
is 0.023. It implies that the DC signals in the CRC dataset are highly sparse.

Figure C.1. Empirical density plot of τb1 for all 949, 280 gene-pair combinations.
The proportion of |τb1 | being less than 0.5 is 0.977.
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Appendix D
Convergence Diagnostics for SPSL and C-SPSL
To examine MCMC convergence in simulations, Gelman-Rubin diagnostics (Gelman
et al., 1992) are used to provide numerical convergence summaries for both the SPSL
model and the C-SPSL model in simulation scenario I. For each simulated dataset
in the 100 simulation iterations, 3 MCMC chains were implemented for deriving
the Gelman-Rubin diagnostics summaries. In this section, we pick one dataset and
present the results of both SPSL and C-SPSL for all parameters in Table D.1 and
Table D.2. As shown in the tables, the Gelman-Rubin statistics are all close to 1,
which indicates good convergence for both SPSL and C-SPSL. In addition, all the
other simulated datasets also have good convergence in MCMC chains.
Moreover, to visualize the convergence for the two models, trace plots generated
from three mixed MCMC chains for all hyperparameters (τ0,j , τ1,j , ϕj , wj , c) in both
models for the same simulatied dataset are presented in Figure D.1 and Figure D.2.
We choose the first gene pair (τ1,1 = 0) and the tenth (τ1,10 = 1) gene pair to show
the convergence results for both zero and non-zero dynamic co-expression (DC) gene
pairs. As presented in the Figures, MCMC chains for all parameters mixed well for
both SPSL and C-SPSL.
The results of Gelman-Rubin diagnostics for the top 30 gene pairs with the largest
|τb1,j | based on Table 3.3 in Section 3.5 from the experimental data analysis are presented in Table D.3. All Gelman-Rubin statistics are close to 1. We also provide
the trace plots for the τ1,j of the top ten gene pairs in Figure D.3. The results of
Gelman-Rubin diagnostics and the trace plots both indicate that the MCMC chains
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mixed well and converged for all the top gene pairs.
Table D.1. Gelman-Rubin diagnostics results for SPSL model with 5 genes (10
pairs) and sample size of 200.

j
1
2
3
4
5
6
7
8
9
10

τ0,j
Point Upper
est.
C.I.
1.00
1.01
1.00
1.00
1.01
1.02
1.01
1.02
1.00
1.01
1.00
1.00
1.01
1.03
1.01
1.02
1.00
1.01
1.00
1.01

τ1,j
Point Upper
est.
C.I.
1.00
1.00
1.00
1.00
1.01
1.02
1.01
1.03
1.00
1.01
1.00
1.00
1.01
1.03
1.01
1.02
1.01
1.02
1.00
1.01

ϕj
Point Upper
est.
C.I.
1.05
1.08
1.03
1.04
1.00
1.02
1.03
1.07
1.08
1.18
1.08
1.17
1.02
1.04
1.00
1.00
1.04
1.09
1.01
1.01

wj
Point Upper
est.
C.I.
1.00
1.00
1.00
1.01
1.00
1.00
1.00
1.00
1.00
1.02
1.01
1.02
1.00
1.00
1.00
1.00
1.00
1.01
1.00
1.00

Table D.2. Gelman-Rubin diagnostics results for C-SPSL model with 5 genes (10
pairs) and sample size of 200.

j
1
2
3
4
5
6
7
8
9
10

Point
est.
1.00
1.00
1.01
1.00
1.01
1.00
1.00
1.01
1.04
1.00

τ0,j
Upper
C.I.
1.01
1.00
1.02
1.01
1.02
1.01
1.01
1.03
1.12
1.01

Point
est.
1.00
1.00
1.01
1.00
1.01
1.00
1.00
1.01
1.05
1.00

τ1,j
Upper
C.I.
1.00
1.00
1.02
1.00
1.03
1.00
1.00
1.03
1.16
1.01
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Point
est.
1.01
1.01
1.05
1.12
1.02
1.01
1.06
1.01
1.09
1.06

ϕj
Upper
C.I.
1.02
1.03
1.11
1.21
1.04
1.02
1.08
1.03
1.23
1.08

Point
est.
1.01
1.01
1.01
1.00
1.00
1.00
1.00
1.01
1.02
1.01

wj
Upper
C.I.
1.02
1.02
1.03
1.01
1.01
1.00
1.00
1.03
1.06
1.03

(a) Trace plots for τ0,10 , τ1,10 , ϕ10 , w10 when τ1,10 = 0.

(b) Trace plots for τ0,10 , τ1,10 , ϕ10 , w10 when τ1,10 = 1.

Figure D.1. Trace plots for SPSL model with sample size of 200.
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(a) Trace plots for τ0,10 , τ1,10 , ϕ10 , w10 when τ1,10 = 0.

(b) Trace plots for τ0,10 , τ1,10 , ϕ10 , w10 when τ1,10 = 1.

Figure D.2. Trace plots for C-SPSL model with sample size of 200. Notice c is a
global parameter for all j.
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Table D.3. Gelman-Rubin diagnostics results of τ1,j for the top 30 gene pairs with
the largest |τb1,j |.
j
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

Gene I
C18orf12
SCEL
POLR3A
MEP1B
PRR16
LOC642696
METTL6
ZMYM2
PIK3CA
KIF19
KCNS1
LINC01013
LOC100129175
PIK3CA
FMN2
SCGB1D2
C16orf74
LOC389199
MYH7B
PLEK
FILIP1L
LOC101928760
MYH7B
LOC101928553
KCNIP2
MEP1B
C11orf42
FAM218A
LOC101928760
LINC00889

Gene II
MEP1B
TGIF1
MEP1B
MIR4500HG
PLAU
DDX25
MEP1B
AMELX
PIP
LOC105379426
TEX48
SMYD1
ZNF787
SCGB1D1
SH2B1
SNHG10
TBC1D21
MYH7B
UCP1
AQP9
GDPD1
TMEM151B
ADARB2
SPINT3
MLANA
NIPAL3
SNHG10
DIPK1B
CLECL1
MEP1B
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Point est. Upper C.I.
1.14
1.40
1.04
1.11
1.00
1.01
1.01
1.02
1.01
1.02
1.01
1.03
1.01
1.01
1.27
1.92
1.00
1.02
1.00
1.01
1.02
1.05
1.01
1.01
1.00
1.00
1.03
1.05
1.00
1.00
1.00
1.01
1.01
1.02
1.01
1.02
1.00
1.01
1.01
1.02
1.00
1.01
1.00
1.01
1.00
1.01
1.01
1.02
1.00
1.01
1.01
1.01
1.07
1.16
1.00
1.00
1.01
1.02
1.00
1.00

Figure D.3. Trace plots of τ1,j for gene pairs with the largest ten |τb1,j | in the
colorectal cancer dataset.
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Appendix E
Determination of the Recurrence-Free Survival
Time
In order to implement the proposed model in the experimental data analysis to identify gene pairs with significant non-zero τ1,j (DC gene pairs) associated with the
recurrence-free survival time, we use individual patients’ recurrence-free survival time
(z) to indicate their ability to survive without CRC recurrence or metastasis after
the surgery. Let Ti be the cancer recurrence-free survival time for subject i. If subject
i experience the CRC recurrence or metastasis after the surgery, then Ti is exactly
observed and will be used for zi . However, if subject i does not experience the CRC
recurrence or metastasis after the surgery, Ti is right-censored at the last examination (or follow-up) time t0,i . In this case, we will use the predictive survival time
E(Ti |Ti > t0,i ) for zi . In the following we describe how we obtain an estimate of
E(Ti |Ti > t0,i ) for right-censored Ti .
Define S(t|ν) = P (T > t|ν) as the marginal probability of T greater than t for a
subject with covariates ν. One can obtain the estimated survival function based on
the observed data using standard statistical packages, such as the survival package
in R (The survival package, 2021). The conditional expectation is calculated as,
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Z ∞

f (t|νi )
dt
P (Ti > t0,i |νi )
t0,i
Z ∞
1
=−
tdS(t|νi )
S(t0,i |νi ) t0,i
(
)
Z ∞
1
t0,i S(t0,i |νi ) +
S(t|νi )dt
=
S(t0,i |νi )
t0,i
Z ∞
1
S(t|νi )dt.
= t0,i +
S(t0,i |νi ) t0,i

E(Ti |Ti > t0,i , νi ) =

t·

(E.1)

One can estimate the above quantity by plugging in the estimated survival function
b
S(t|ν)
for S(t|ν). To calculate the integral, we propose to use importance sampling

as follows. Given a set of samples ω1 , ..., ωl sampled from the proposal distribution
with pdf g(·), the estimator for
Z ∞
t0,i

R∞ b
S(t|ν
t0,i

b
S(t|ν

i )dt

=

i )dt

Z ∞ b
S(t|νi )
t0,i

= Eg (
≃

is given by the following equation,

g(t)

· g(t)dt

b
S(t|ν
i)
)
g(t)

(E.2)

l b
1X
S(ωk |νi )
,
l k=1 g(ωk )

νT β
b
b (t) is the
where Sbi (t|νi ) = e−Λb0 (t)e i is the estimator of the survival function, Λ
0

estimated cumulative baseline hazard function at time t and βb is the estimated coefficient vector. The covariates νi are specified as patients age, gender, and stage of
colorectal cancer before surgery. Here we take the shifted exponential distribution
g(t) = e−(t−t0,i ) I(t > t0,i ) as the proposal distribution in the sampling process. The
number of samples of the proposal distributions l = 1, 000 ensures the accuracy of
the approximation.
Algorithm 3 below summarizes how we obtain the predictive survival E(Ti |Ti >
t0,i ) for right-censored observation i. The survival time for right-censored records are
approximated using the predicted survival.
After calculating the expected survival times E(Ti |Ti > t0,i ) for right-censored
observations, we can derive the covariate vector z as described above. At the end,
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Algorithm 3: Calculate the expected survival times for right-censored observations
1. Build Cox model with covariates ν (for all observations).
2. Sample ω1 , ...ω1000 from g(t) = e−(t−t0,i ) I(t > t0,i ) for the i-th observation.
S (ωk |νi )
b
3. Estimate S(·|ν
i ) and calculate g(ωk ) , k = 1, ..., l.
4. Approximate the predictive survival E(Ti |Ti > t0,i , νi ) using

b

t0,i + Sb(t 1 |ν ) ×
0,i i

1
l

Pl

k=1

b(ωk |νi )
S
.
g(ωk )

the recurrence-free survival time estimates are re-scaled by the maximum value so
that each zi is within (0, 1].
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